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Summary
The ultimate consequence of the interruption of blood flow to the myocardium is
necrosis. In view of the prevalence of coronary artery disease in the general
population, and the deleterious effects of myocardial ischaemia on myocardial
tissue, it is important to develop new strategies to protect the myocardium against
ischaemia. Necrosis of myocardial tissue has for a long time been considered to be
the main component of the damage incurred by myocardial infarction. Recently the
importance of the contribution of apoptotic cell death in the context of myocardial
ischaemia/reperfusion injury has become apparent.
There is a general agreement that early reperfusion is necessary to salvage
myocardial tissue from cell death. Preconditioning is the phenomenon whereby
brief episodes of ischaemia and reperfusion protect the heart against a subsequent
longer period of ischaemia. This endogenous mechanism is the strongest form of
protection against myocardial infarction that has yet been described. Apart from
ischaemie preconditioning (IPC), protection can also be elicited with pharmacologic
agents, such as activation of the beta-adrenergic receptor with isoproterenol.
Ischaemie preconditioning protects the myocardium against necrosis, arrhythmias
and apoptosis, and increases functional recovery upon reperfusion. Beta-
adrenergic receptor stimulated preconditioning (PPC) has been shown to improve
post-ischaemie functional recovery, but it is not known whether it also protects
against myocardial infarction and apoptosis.
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The signaling pathways involved in preconditioning have been extensively studied.
A distinction is usually made between factors that act as triggers, or as mediators
of protection. Triggers activate cellular responses before the onset of sustained
ischaemia, and its involvement is demonstrated by showing that inhibitors of the
trigger bracketing the preconditioning protocol can block its protective effect, or that
transient administration with washout before sustained ischaemia can activate a
protective effect. A mediator operates during sustained ischaemia, and its
involvement is demonstrated by showing that infusion of an inhibitor of its action
immediately prior to sustained ischaemia (without washout) can block its protective
effect. Another approach to demonstrate a mediator role is to attempt to activate
signal transduction pathways during sustained ischaemia. As it is not possible to
infuse substances during ischaemia, activators are infused immediately prior to
ischaemia without washout of the agent and subsequently its effect on protection is
observed.
It is clear that the evolutionary conserved stress activated pathways are involved in
preconditioning. There are three pathways i.e., the extracellular receptor activated
pathways (ERK), c-jun terminal activated kinases (JNK) and p38 mitogen-activated
protein kinases (MAPK). The precise role of the p38 MAPK pathway has not been
elucidated. Experimental evidence has suggested a role for the activation of p38
MAPK as a trigger, as well as a mediator of the protective effect of preconditioning.
There is however also strong evidence that the attenuation of p38 MAPK activation
during sustained ischaemia, rather than its activation, is responsible for the
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investigated in relation to its protection against necrosis, but not apoptosis.
AIMS:
The aim of this study was to:
(I) Establish a model of preconditioning in neonatal cardiomyocyte cell culture.
The reason was that such a model could potentially enable one to rapidly
elucidate the signal transduction pathways in an environment without the
influence of non-cardiac cells.
(II) Investigate whether IPC and ~PC protect against necrosis and apoptosis.
(III) Elucidate the role of the stress-activated kinase, p38 MAPK, in
preconditioning.
METHODS:
1. Neonatal rat cardiomyocyte cell culture model
A viability assay with 3-[4,5- Dimethylthaizol-2-yl]-2,5-diphenyl-tetrazolium bromide
(MTT) was first developed using different concentrations - a concentration of
0.25% was found to be optimal to determine viability. Neonatal cardiomyocyte cell
cultures were subjected to sustained simulated "ischaemia" by using either 5 mM
KCN plus deoxyglucose (DOG) for 5 min or potassium cyanide (KCN) for 45 min.
Some cell cultures were preconditionedwith either chemical ischaemia (5 mM KCN
for 5 min) or isoproterenol (10-7 M) for 5 min and 60 min reoxygenation before
being exposed to sustained simulated ischaemia.
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2. Isolated adult rat cardiomyocyte model
Isolated cardiac myocytes were exposed to 2 hours of hypoxia, which was induced
by pelletting the cells by centrifugation, and covering them with a thin layer of
mineral oil. Some groups were preconditioned with either hypoxia for 10 min at
37° C or isoproterenol (10-7M) for 5 min, followed by reoxygenation for 20 minutes.
The trypan blue exclusion method and MTT method developed in the neonatal
cardiomyocytes were used to assess viability.
3. Isolated perfused rat heart model
3.1 Infarct size was determined in a model of regional ischaemia by using
tetrazolium staining and determining the area of necrosis (exclusion of
tetrazolium) as a percentage of area at risk. These hearts were subjected to
35 min global ischaemia and 30 min reperfusion. Some groups were
preconditioned by three cycles of 5 min global ischaemia or addition of
isoproterenol (10-7 M) for 5 min, followed by 5 min reperfusion before the
onset of sustained regional ischaemia.
3.2 p38 MAPK activation and markers of apoptosis: p38 MAPK activation was
determined using antibodies against dual phosphorylated p38 MAPK (i.e.
activated p38 MAPK). Apoptosis was measured by using antibodies against
activated caspase-3, and against a fragment of PARP (PARP cleavage). For
these experiments isolated rat hearts were exposed to global ischaemia for
25 min followed by 30 min reperfusion. Some groups were preconditioned
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with three cycles of 5 min global ischaemia. A global ischaemia model was
used in order to have sufficient tissue available for the Western blot
determinations. This necessitated a shorter period of sustained ischaemia,
as the globally ischaemie heart does not recover sufficiently after a longer
period of ischaemia such as is necessary in regional ischaemia
experiments.
3.3 The role of p38 MAPK in ischaemie preconditioning was investigated by
administration of SB 203580 (1IJM),a selective inhibitor of p38 MAPK, either
bracketing the preconditioning (i.e. to determine its role as a trigger) or for
10 min immediately prior to sustained ischaemia (i.e. to determine its role as
a mediator). The second approach was to use anisomycin, an activator of
p38 MAPK, as a trigger (infusion for 10 min followed by wash out) or as a
mediator (10 min immediately prior to sustained ischaemia) in the same
model as used for determination of p38 MAPK activity. The infusion of
anisomycin for 10 min has been shown to elicit activation of p38 MAPK to a
similar extent as has been observed with an ischaemie preconditioning
protocol. The endpoints used were infarct size and markers of apoptosis.
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RESULTS:
1. Neonatal rat cardiomyocyte cell culture model
It was not possible to establish a model of preconditioning of neonatal
cardiomyocytes that was consistently successful. It was therefore decided to
abandon the attempts and to use a different cell model.
2. Isolated adult rat cardiomyocyte model
Isolated adult cardiomyocytes were preconditioned successfully, but produced too
little material to perform simultaneous determinations of cell viability and Western
blots (p38 MAPK activation and markers of apoptosis). It was therefore decided to
use the isolated perfused adult rat heart.
3. Isolated perfused adult rat heart model
3.1 Both IPC and PPCprotect against infarction and apoptosis:
Using two models of preconditioning i.e., IPC and PPC, the protective effects of
preconditioning were demonstrated convincingly against infarction (necrosis). IPC
and PPC both caused a significant reduction in infarct size (12.2±1.4 and
15.2±2.6%) versus Non-PC hearts (29.6±2.9%) (p < 0.001). Both forms of
preconditioning also protected against apoptosis, by significantly reducing the
markers of apoptosis, caspase-3 activation and PARP cleavage. The protection
afforded by both forms of preconditioning was accompanied by a marked decrease
in activation of p38 MAPK upon reperfusion. The relationship between p38 MAPK
and the protection that was elicited by preconditioning was then investigated,
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namely whether p38 MAPK acted as a trigger, or as a mediator of protection. To
investigate the role of p38 MAPK as a mediator or a trigger in preconditioning, use
was made of (i) a specific inhibitor of p38 MAPK activation i.e., SB 203580 and (ii)
a known activator of p38 MAPK i.e., anisomycin.
3.2 p38 MAPK as a trigger of protection:
Administration of SB 203580 during the IPC protocol and washed out before
sustained ischaemia did not abolish the protective effect of ischaemie
preconditioning, and resulted in a small, but significant increase in caspase-3
activation and PARP cleavage. On the other hand, activation of p38 MAPK with
anisomycin for 10 min followed by washout also resulted in a significant reduction
in necrosis (infarct size 14.9±2.2 versus 29.6±2.9% in Non-PC hearts) (p < 0.001)
and both markers of apoptosis. The latter results suggested that p38 MAPK was a
trigger of preconditioning. If this was the case, why didn't SB 203580 abolish the
protection of IPC? The most likely explanation was that multiple protective
mechanisms were activated during a multi-cycle protocol of ischaemic
preconditioning, of which activation of p38 MAPK was only one. Inhibition of p38
MAPK with SB 203580 would therefore not be expected to block the activation of
those mechanisms that were independent of p38 MAPK, but were still capable of
protecting against necrosis or apoptosis. It is very interesting that a small increase
in apoptosis was observed when SB 203580 was used in this situation, as it may
indicate that the protection against apoptosis was more dependent on the
activation of p38 MAPK than the protection against necrosis, as no effect was seen
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sensitive enough to detect such small effects.
3.3 p38 MAPK as a mediator of protection:
Inhibition of p38 MAPK activation with SB 203580 administered 10 min before
sustained ischaemia caused a significant decrease in infarct size compared to
Non-PC hearts (12.6±1.9 vs 29.6±2.9%) (p < 0.001) equivalent to that of hearts
preconditioned with ischaemia. This was accompanied by a similar pattern of
protection against apoptosis, with significantly reduced activation of caspase-3
activation and PARP cleavage.
These results strongly supported a role for the attenuation of p38 MAPK activation
as a mediator of preconditioning against ischaemia/reperfusion-mediated necrosis
and apoptosis. However, the results of the experiments with anisomycin were at
first glance not compatible with such a conclusion. The administration of the
activator of p38 MAPK, anisomycin, for 10 min immediately prior to sustained
ischaemia resulted in significant protection against necrosis (infarct size 16.6±2.4%
vs 29.6±2.9% in Non-PC hearts) (p < 0.01) and reduced caspase-3 activation and
PARP cleavage indicating less apoptosis. The reason for these findings were
probably that this method of administration of anisomycin did in fact not activate
p38 MAPK during sustained ischaemia, but actually served as a trigger to protect
against ischaemia - similarly as if it had been infused with washout of the drug.
Support for this notion was found in the fact that p38 MAPK activation was
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decreased upon reperfusion. These results suggested that the logistical problem of
not being able to infuse a drug into the myocardium during ischaemia could not be
overcome by immediate prior infusion, and that the administration of anisomycin in
this way had activated downstream effectors of the p38 MAPK signal transduction
pathway. An important contender for such an effector would be heat shock protein
27 (HSP27), which has been shown to play an important role in protection against
apoptosis, and stabilisation of actin, and thus the cytoskeleton. Another possibility
was that anisomycin had activated the JNK stress activated kinases. The
elucidation of a role of this signal transduction pathway would necessitate the use
of anisomycin in the presence of an agent such as curcumin, an inhibitor of JNK.
Final conclusion:
The work in this thesis showed that the stress activated kinase, p38 MAPK, was
involved in the protective effect of ischaemie preconditioning. The results
suggested a role for the activation of p38 MAPK as a trigger of protection, and the
attenuation of p38 MAPK as a mediator of protection, which was observed in the
reduction of both necrosis (infarct size) and apoptosis as determined with caspase-
3 activation and PARP cleavage.
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Opsomming
Die afsluiting van bloedvloei na die miokardium gee aanleiding tot nekrose. In die
lig van die voorkoms van koronêre bloedvatsiekte onder die algemene populasie,
en die nadelige effekte van miokardiale isgemie op miokardiale weefsel, is dit
belangrik om nuwe strategieë te ontwikkel wat die miokardium teen isgemie
beskerm. Nekrose van miokardiale weefsel word tradisioneel as die belangrikste
komponent van die skade aangerig deur miokardiale infarksie beskou. Die belang
van apoptotiese seldood in die konteks van miokardiale isgemie/herperfusie (I/R)
het onlangs na vore getree.
Dit word algeneem aanvaar dat vroeë vroegtydige herperfusie noodsaaklik is om
miokardiale weefsel te beskerm teen seldood. Prekondisionering is 'n verskynsel
waartydens kort episodes van IIR die hart teen 'n daaropvolgende langer periode
van isgemie beskerm. Hierdie endogene meganisme is die kragtigste vorm van
beskerming teen miokardiale infarksie tot dusver beskryf. Afgesien van isgemiese
prekondisionering (IPC), kan beskerming ook deur farmakologiese middels, soos
byvoorbeeld die aktivering van die beta-adrenerge reseptore met isoproterenol,
ontlok word. IPC beskerm die miokardium teen nekrose, arritmieë en apoptose, en
verhoog funksionele herstel na herperfusie. Daar is reeds aangetoon dat beta-
adrenerge prekonsionering (~PC) post-isgemiese funksionele herstel verbeter,
maar dit is nog onbekend of beskerming ook teen miokardiale infarksie en
apoptose verleen word.
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Die seintransduksie paaie betrokke tydens prekondisionering is reeds in detail
bestudeer. Daar word gewoonlik tussen faktore wat optree as snellers, of as
mediators van beskerming, onderskei. Snellers aktiveer sellulêre response voor die
aanvang van volgehoue isgemie, en hul betrokkenheid word aangetoon deurdat
inhibisie van snellers tydens die prekondisionering protokol, beskerming ophef.
Snellers se effekete kan ook ontlok word deur hulle tydelike toe te dien en dan net
voor volgehoue isgemie weer uit te was. Mediators oefen hulle effek tydens
volgehoue isgemie uit, en hulle betrokkenheid word gedemonstreer deurdat
toediening van inhibitors net voor volgehoue isgemie (sonder uitwas) hulle
beskermende effekte ophef. Mediators se rol kan ook aangetoon word deur te
poog om seintransduksie paaie tydens volgehoue isgemie te aktiveer. Aangesien
dit ontmoontlik is om middels tydens isgemie te infuseer, word aktiveerders
onmiddelik voor die aanvang van isgemie toegedien sonder om hulle uit te was,
sodat hulle effekte op beskerming vervolgens bestudeer kan word.
Dit is duidelik dat die evolusionêr-behoue stres geaktiveerde paaie tydens
prekondisionering betrokke is. Daar is drie paaie nl. die ekstrasellulêre reseptor
geaktiveerde pad (ERK), c-jun terminaal geaktiveerde kinases (JNK) en p38
mitogeen geaktiveerde proteïen kinases (MAPK). Die spesifieke rol van die p38
MAPK pad is nog nie ontrafel nie. Eksperimentele bewyse stel 'n rol vir die
aktivering van p38 MAPK as 'n sneller, sowel as 'n mediator van die beskermende
effek van prekondisionering, voor. Daar is egter ook sterk bewyse dat 'n afname in
p38 MAPK aktivering tydens volgehoue isgemie, eerder as sy aktivering,
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verantwoordelik is vir die waargenome beskermende effek. Verder is die rol van
p38 MAPK slegs in die konteks van beskerming teen nekrose, maar nie teen
apoptose nie, bestudeer.
DOELWITTE:
Die doelwit van hierdie studie was:
(I) Die vestiging van 'n prekondisionering model in neonatale kardiomiosiet in
selkultuur. Hierdie model sou potensieel 'n spoedige ontrafeling van die
seintransduksie paaie sonder die invloed van nie-kardiale selle bewerkstellig.
(II Om ondersoek in te stelof IPC en PPCteen nekrose en apoptose beskerm.
(III) Die ontrafeling van die rol van die stres geaktiveerde kinase, p38 MAPK,
tydens prekondisionering.
METODES:
1. Neonatale rot kardiomiosiet weefselkultuur model
'n Lewensvatbaarheids essai is ontwikkel deur van verskillende konsentrasies van
3-[4,5-dimetielthiazol-2-yl]-2,5-difeniel-tetrazolium bromied (MTT) gebruik te maak
- 'n konsentrasie van 0.25% was optimaalom lewensvatbaarheid te bepaal.
Neonatale kardiomiosiet weefselkulture is onderwerp aan volgehoue gesimuleerde
"isgemie" deur gebruik te maak van 5 mM KCN plus deoksiglukose (DOG) vir 5
minute of 45 min KCN. Sommige weefselkulture is geprekondisioneer deur middel
van chemiese isgemie (5 mM KCN vir 5 min) of van isoproterenol (10-7 M) vir 5
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minute en 60 minute reoksigenasie alvorens dit bloot gestel is aan volgehoue
gesimuleerde isgemie.
2. Geïsoleerde volwasse rot kardiomiosiet model
Geïsoleerde kardiomiosiete is aan twee uur hipoksie blootgestel deur selle in 'n
pellet te sentrifugeer en met 'n dun lagie mineraalolie te bedek. Sommige groepe is
geprekondisioneer deur middel van 10 minute hipoksie by 37°C, of toediening van
isoproterenol (10-7 M) vir 5 minute gevolg deur 20 minute reoksigenasie. Die
tripaanblou uitsluitings metode en MTT metode soos ontwikkel in die neonatale
kardiomiosiet model is gebruik om lewensvatbaarheid te bepaal.
3. Geïsoleerde geperfuseerde volwasse rot hart model
3.1 Infarkgrootte is bepaal met 'n model van streeks isgemie deur van
tetrazolium kleuring gebruik te maak, waarna die area van nekrose (uitsluiting van
tetrazolium) as 'n presentasie van die risiko area bepaal is. Hierdie harte was
onderwerp aan 35 minute globale isgemie en 30 minute herperfusie. Sommige
groepe is geprekondisioneer met 3 siklusse van 5 minute globale isgemie, of die
toevoeging van isoproterenol (10-7 M) vir 5 minute, gevolg deur 5 minute
herperfusie voor die aanvang van volgehoue streeks isgemie.
3.2 p38 MAPK aktivering en merkers van apoptose: p38 MAPK aktivering is
bepaal deur gebruik te maak van anti-liggame teen tweeledige gefosforileerde p38
MAPK (d.w.s. geaktiveerde p38 MAPK). Apoptose is bepaal deur gebruik te maak
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van anti-liggame teen geaktiveerde kaspase-3, en teen 'n fragment van PARP
(PARP kliewing). Tydens hierdie eksperimente is geïsoleerde rotharte bloot gestel
aan 25 minute globale isgemie gevolg deur 30 minute herperfusie. Sommige
groepe is geprekondisioneer met drie siklusse van 5 minute globale isgemie. Om
voldoende weefsel vir Westerse klad tegnieke te verkry, is gebruik gemaak van 'n
globale isgemie model. As gevolg hiervan was 'n kort periode van volgehoue
isgemie genoodsaak, aangesien die globale isgemiese hart nie voldoende herstel
na 'n langer periode van isgemie nie, soos wat benodig word in streeks isgemiese
eksperimente.
3.3 Die rol van p38 MAPK tydens IPC is bepaal deur die toediening van 'n 1IJM
konsentrasie van SB 203580, 'n selektiewe inhibitor van p38 MAPK, hetsy tydens
prekondisionering (d.w.s. om die rol as 'n sneller te bepaal), óf vir 10 minute direk
voor die aanvang van volgehoue isgemie (d.w.s. om dus sy rol as mediator te
bepaal). Die tweede benadering was om anisomisien, 'n aktiveerder van p38
MAPK, as sneller (toediening vir 10 minute gevolg deur uitwassing) of as mediator
(10 minute direk voor aanvang van volgehoue isgemie) in dieselfde model as in die
geval van p38 MAPK aktiviteit bepaling, te gebuik. Die toediening van anisomisien
vir 10 minute het aangetoon dat dit p38 MAPK aktivering kan ontlok tot dieselfde
maate as die IPC protokol. Die eindpunte was infarkgrootte en merkers van
apoptose.
Stellenbosch University http://scholar.sun.ac.za
xvii
RESULTATE:
1. Neonatale rot kardiomiosiet weefselkultuur model
Dit was nie moontlik om 'n suksesvolle model met konsekwente resultate vir die
prekondisionering van neonatale kardiomiosiete te vestig nie. Daar is dus besluit
om af te sien van hierdie pogings en eerder 'n alternatiewe selmodel te gebruik.
2. Geïsoleerde volwasse rot kardiomiosiet model
Geïsoleerde volwasse kardiomiosiete is suksesvol geprekondisioneer, maar het te
min materiaalopgelewer vir die gelyktydige bepaling van sellewensvatbaarheid,
p38 MAPK aktivering en merkers vir apoptose. Daar is dus besluit om die
geïsoleerde geperfuseerde volwasse rothart te gebruik.
3. Geïsoleerde geperfuseerde volwasse rothart model
3.1 Beide IPC en PPCbeskerm teen infarksie en apoptose:
Deur gebruik te maak van twee prekondisionering modelle d.w.s. IPC en PPC, is
die beskermende effekte van prekondisionering teen infraksie (nekrose) oortuigend
gedemonstreer. Beide IPC en PPC het In betekenisvolle afname in infarkgrootle
veroorsaak (12.2 ± 1.4 en 15.2 ± 2.6% respektiewelik), vs Nie-PC harte (29.6 ±
2.9%)(p < 0.001). Beide vorme van prekondisionering het ook teen apoptose
beskerm deur die apoptose merkers, kaspase-3 aktivering en PARP kliewing te
verlaag. Die beskerming verkry deur beide vorms van prekondisionering is
geassosieer met In merkbare afname in die aktivering van p38 MAPK na
herperfusie. Die verband tussen p38 MAPK en die beskerming ontlok deur
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prekondisionering is gevolglik ondersoek, naamlik of p38 MAPK optree as 'n
sneller of as 'n mediator van beskerming. Om die rol van p38 MAPK as 'n mediator
of sneller tydens prekondisionering te ondersoek is daar gebruik gemaak van (I) 'n
spesifieke inhibitor van p38 MAPK aktivering nl. SB 203580 en (II) 'n bekende
aktiveerder van p38 MAPK nl. anisomisien.
3.2 p38 MAPK as 'n sneller vir beskerming:
Toediening van SB 203580 tydens die IPC protokol en uitwassing daarvan voor die
aanvang van volgehoue isgemie het nie die beskermende effek van IPC opgehef
nie, en het gelei tot 'n klein maar betekenisvolle verhoging in kaspase-3 aktivering
en PARP kliewing. Andersins het die aktivering van p38 MAPK met anisomisien vir
10 minute gevolg deur In uitwas ook tot In betekenisvolle afname in nekrose
(infarkgrootte 14.9 ± 2.2 vs 29.6 ± 2.9% in Nie-PC harte) (p < 0.001) in beide
merkers van apoptose gelei. Laasgenoemde resultate dui daarop dat p38 MAPK
inderdaad 'n mediator van prekondisionering is. Indien dit die geval is, waarom het
SB 203580 nie die beskermende effek van IPC opgehef nie? Die mees
waarskynlike verklaring is dat veelvuldige beskermingsmeganismes tydens 'n
multi-siklus protokol van IPC geaktiveer word, waarvan p38 MAPK aktivering slegs
een is. Dit is dus onwaarskynlik dat die inhibisie van p38 MAPK met SB 203580 die
aktivering van daardie meganismes onafhanklik van p38 MAPK sal blokkeer en
steeds in staat sal wees tot beskerming teen nekrose en apoptose. Dit is
interessant dat In klein verhoging in apoptose waargeneem is toe SB 203580
gebruik is onder hierdie toestande, aangesien dit daarop kan dui dat die
Stellenbosch University http://scholar.sun.ac.za
xix
beskerming teen apoptose meer afhanklik was van die aktivering van p38 MAPK
as die beskerming teen nekrose, siende dat geen effek op infarkgrootte
waargeneem is nie. 'n Verdere verklaring kan wees dat die bepaling van
infarkgrootte nie sensitief genoeg is om sulke klein effekte waar te neem nie.
3.3 p38 MAPK as 'n mediator vir beskerming:
Inhibisie van p38 MAPK aktivering deur SB 203580 toediening 10 minute voor
volgehoue isgemie het 'n betekenisvolle verlaging in infarkgrootte in vergelyking
met Nie-PC harte veroorsaak (12.6 ± 1.9 vs 29.6 ± 2.9%) (p < 0.001) soortgelyk
aan dié van harte geprekondisioneer met isgemie. Dit is geassosieer met In
soortgelyke patroon van beskerming teen apoptose, met betekenisvolle verlaagde
kaspase-3 aktivering en PARP kliewing.
Hierdie resultate ondersteun die rol van die afname van p38 MAPK aktivering as 'n
mediator van prekondisionering teen I/R-gemedieerde nekrose en apoptose. Die
resultate van die anisomisien eksperimente was met die eerste oogopslag nie in
oorstemming met hierdie gevolgtrekking nie. Die toedienning van die p38 MAPK
aktiveerder, anisomisien, vir 10 minute voor volgehoue isgemie het tot 'n
betekenisvolle beskerming teen nekrose aanleiding gegee (infarkgrootte 16.6 ± 2.4
vs 29.6 ± 2.9% in Nie-PC harte) (p < 0.01) en verlaagde kaspase-3 aktivering en
PARP kliewing wat dui op verlaagde apoptose. Die rede vir hierdie bevindings is
moontlik dat die metode van anisomisien toediening nie p38 MAPK geaktiveer het
tydens volgehoue isgemie nie, maar eintlik gedien het as 'n sneller vir beskerming
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teen isgemie - amper asof dit toegedien sou word sonder om uitgewas te word.
Ondersteuning vir hierdie aanname word gevind in die feit dat p38 MAPK
aktivering verlaag is na herperfusie. Hierdie resultate stel voor dat die logistiese
probleem dat In middel nie tydens isgemie toegedien kan word nie, nie oorkom kan
word deur onmiddelike voortydige infusie nie, en dat die toediening van
anisomisien op hierdie manier gelei het tot die aktivering van stroom-af effektors
van die p38 MAPK seintransduksie pad. 'n Belangrike kandidaat vir so 'n effektor is
"heat shock protein 27" (HSP27), wat reeds aangetoon is om 'n belangrike rol in
die beskerming teen apoptose en destabilisering, en dus die sitoskelet, te speel. 'n
Ander moontlikheid is dat anisomisien die JNK stres geaktiveerde kinases
geaktiveer het. Die ontrafeling van die rol van hierdie seintransduksie pad
noodsaak die gebruik van anisomisien in die teenwoordigheid van 'n agent soos
curcumin, 'n JNK inhibitor.
Finale gevolgtrekking:
Die werk soos vervat in hierdie tesis toon aan dat die stres geaktiveerde kinase,
p38 MAPK, betrokke is in die beskermings effek van isgemiese prekondisionering.
Die resultate dui op 'n rol vir die aktivering van p38 MAPK as 'n sneller vir
beskerming, en die afname in p38 MAPK as 'n mediator vir beskerming, soos
waargeneem in die vermindering van veranderlikes van beide nekrose
(infarkgrootte) en apoptose soos bepaal deur kaspase-3 aktivering en PARP
kliewing.
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Chapter 1
Literature Review
1.1 Introduction
The inevitable consequence of the abrupt deprivation of oxygen supply to the
myocardium is myocardial infarction. Living systems have the ability to respond to
stresses that endanger the survival of the organism to minimize the damage that is
incurred. An example of such cytoprotection is ischaemie preconditioning, the
phenomenon whereby brief episodes of ischaemia and reperfusion protects the heart
against a subsequent period of sustained ischaemia (Murray et al 1986). Ischaemie
preconditioning has been shown to be a potent endogenous protective mechanism to
reduce infarct size during ischaemia/reperfusion.
Myocardial ischaemia/reperfusion injury-induced tissue loss has long been
considered to only involve necrosis of myocardial cells. There is however growing
evidence that apoptosis also makes an important contribution to
ischaemia/reperfusion damage (Bardales et al 1996, Colucci et al 1996, Haunstetter
et al 1998, Itoh et al 1995, Saraste et al 1997, Yeh et al 1997). In fact, Anversa et al
(1998) has shown that apoptosis is the predominant mode of cell death in
ischaemia/reperfusion. A critical role for apoptosis has also been suggested in
several other cardiovascular diseases e.g., in myocardial ischaemia/reperfusion both
in vitro (Umansky et al 1995) and in vivo (Gottlieb et al 1994), acute myocardial
infarction (Olivetti et al 1996, Saratse et al 1997), myocarditis (Bachmaier et al 1997),
heart failure (Bing et al 1994, Naruia et al 1996, Sharov et al 1996), and ischaemie
cardiomyopathy (Olivetti et al 1997).
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2Much is known concerning the signal transduction pathways involved in ischaemie
preconditioning with infarct size as end-point. With the emergence of an increased
understanding of the important role of apoptosis in cell death during
ischaemia/reperfusion, it has become important to elucidate the role of these
signaling pathways in apoptosis in order to develop new therapeutic strategies.
This review of the literature will summarize the known data concerning (i) the
biological phenomenon of preconditioning, (ii) the signal transduction pathways
involved in eliciting and mediating the protection, (iii) the ability of preconditioning to
protect against apoptosis and (iv) the signal transduction pathways implied in the
protection against apoptosis.
1.2 Preconditioning (PC)
Preconditioning is the phenomenon whereby exposure to one or more brief episodes
of ischaemia renders the heart more resistant to a subsequent sustained period of
ischaemia. This phenomenon known as ischaemie preconditioning (IPC), was first
described by Murry et al (1986) in the canine heart where it protected against the
damaging consequences of ischaemia/reperfusion (I/R) injuries. Subsequently this
phenomenon has been shown in all animal species studied (Barbosa et al 1996, Li et
a11992a, Liu Yet a11992, Schott et a11990, Wolfe et aI1993,) including humans
(Deutsch et al 1990, Kloner et al 1994, Ottani et al 1995, Yellon et al 1993, Yellon et
al 2000). The protection of IPC is manifested on different end-points: functional
recovery, arrhythmias and the most widely studied, necrosis. Recently the protection
of IPC has also been shown in apoptosis (see later).
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3There is a general agreement that other than expedited reperfusion, preconditioning
is the strongest form of in vivo protection against myocardial ischaemie injury
(National Heart, Lung and Blood Institute (NHLBI) workshop- Kloner et al 1998).
The phenomenon described by Murry et al is now referred to as "classical" or "early"
ischaemie preconditioning which, while powerful, lasts only 1-2 hours (Bolli et al
2000). A second phase of preconditioning, called the Second Window Of
Preconditioning (SWap), appears 12-24 hours after preconditioning and although
less potent, can last for up to 3 days (Bolli et al 2000).
1.2.1 Triggers and mediators of preconditioning
In addition to brief episodes of ischaemia-reperfusion a variety of preconditioning
stimuli such as hypoxia (Cohen et al 1995), rapid cardiac pacing (Vegh et al 1991,
Koning et al 1996), thermal stress (Cumming et al 1996), stretch (Gysembergh et al
1998, Ovize et al 1994), and pharmacological agents (Yellon et al 1998, Cohen et al
2000) are known. These triggers put into motion a series of events that eventually
mediate the cardioprotection characteristic of PC. In other words, the myocardium
"remembers" that it has been preconditioned. Unravelling the mechanism(s) of this
"memory" remains to be established.
Triggers can be tested experimentally by administering the agent to the heart for a
limited period followed by a wash-out period before sustained ischaemia, while
mediators of protection are evaluated by administration just prior to the sustained
ischaemia (without the washout period). Norepinephrine, endothelin, and angiotensin
are examples of neurohumoral agonists that can precondition the heart when
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4administered exogenously but which are not released in sufficient quantities by the
ischaemie myocardium to trigger protection endogenously (Schulz et al 2001 b).
The term pharmacological preconditioning (Cohen et al 1993, Jennings et al 1996)
refers to the condition where pharmacological agents given before coronary
occlusion reduces myocardial infarct size by stimulating second messenger pathways
thought to be involved in preconditioning. Examples of this kind of preconditioning
include administration of adenosine A1 agonists, KATP channel openers, and p-
adrenergic receptor agonists. These agents are referred to as "preconditioning
mimeties" (Kloner et al 1994).
1.2.2 Signal transduction in ischaemie preconditioning
Endogenous triggers eliciting ischaemie preconditioning may be either receptor-
dependent or receptor-independent. Downey and colleagues (Cohen et al 1996,
Goto et al 1995, Liu et al 1991, Ytrehus et al 1994) have proposed that in the rabbit,
the mechanism of preconditioning involves the stimulation and action of the receptor-
dependent endogenous triggers. These include amongst others adenosine,
bradykinin, opioids, endogenous catecholamines, prostaglandins, angiotensin, and
endothelin. The roles of these triggers were evaluated by using either specific
agonists or antagonists of the particular receptor being studied.
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1.2.2.1
5
Receptor-dependent triggers
1.2.2.1.1 Adenosine
The first signal transduction element to be identified as part of preconditioning's
mechanism was the adenosine receptor (Liu et al 1991). An increase in the interstitial
adenosine concentration during the preconditioning ischaemia occurs in rats (Kuzmin
et al 2000), rabbits (Lasley et al 1995, Miura 1996, Mortimer et al 2000), dogs (Mei et
al 1998), and pigs (Martin et a11997, Schulz et al 1995, Wikstrom et al 1995).
Adenosine receptors exist as at least four different subtypes: A1, A2A, A2B, A3
(Aucampach et al 1999, Feoktistov et al 1997, Olah et al 1995). Stimulation of the A1
receptor with N6- (phenyl-2R-isopropyl)-adenosine (PIA) or 2-chloro-N6-
cyclopentyladenosine (CCPA) mimicked IPC in the rabbit, whilst stimulation of the A2
receptor with CGS 21688, had no protective effect (Thornton et al 1992). Stimulation
of the A3 receptor with N6- [2-(4-aminophenyl) ethyl] adenosine (APNEA) was also
able to induce protection (Liu GS et al 1994). Therefore, at least in the rabbit, both
the A 1 and A3 receptors are thought to be involved in triggering cardioprotection. In
the review by Ganote et al (2000) growing evidence suggests that the A 1 receptor is
not required for IPC in the rat heart. This, coupled with a low tissue density of A3-
receptors, coupled with adenosine's very low A3 ligand affinity in rats (Van Wylen
1994) may limit the ability of adenosine to precondition via this receptor in this
particular animal.
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61.2.2.1.2 Bradykinin
Stimulation of bradykinin B2 receptors results in enhanced formation of prostacyclin
and nitric oxide (NO) in cultured human and bovine endothelial cells (Linz et al 1992).
Both prostaglandins (Farber et al 1988, Farber et al 1990) and NO (Gelvan et al
1991) have been demonstrated to attenuate ischaemia/reperfusion injury. Bradykinin
also acts as a trigger in ischaemie preconditioning (Goto et al 1995, Wall et al 1994).
From their experiments in rabbits, Goto et al (1995) found that infusion of the
selective bradykinin B2 receptor antagonist HOE 140 before a single 5 min ischaemie
event completely blocked protection in anaesthetised rabbits. Conversely, brief
infusion of bradykinin reduced infarction. The response to bradykinin was similar to
that of adenosine. Presumably the ischaemie heart releases both adenosine and
bradykinin in amounts that are ineffective alone, but when combined are able to
reach the threshold for cardioprotection (Cohen et al 2000). It was therefore
proposed that additive interactions of triggers contribute to the initiation of ischaemie
preconditioning.
1.2.2.1.3 Opioids
Both adenosine and the release of endogenous opioids appear to trigger ischaemie
preconditioning in an interactive fashion in several species (Fryer et al 1999b, Schulz
et al 1995, Schultz et al 1997). It has been found that naloxone, an opioid antagonist,
can block the PC protection in rats (Fryer et al 1999b, Schultz et al 1995, Schultz et
al 1997), rabbits (Chien et al 1999, Miki et al 1998), and pigs (Schulz et al 2001 a)
Stellenbosch University http://scholar.sun.ac.za
7suggesting a trigger action. It has been shown by Aitchinson et al (2000) that
pharmacological preconditioning with DADLE [D-ala (2), D-leu(5)] enkaphalin]
(10 nmol/L), a synthetic delta-opioid receptor agonist, resulted in similar infarct size
reduction as was seen with IPC (2 cycles of 5 min global ischaemia).
Furthermore, since opiates are known to have anti-adrenergic effects, which
hypothetically may help to mediate IPC, cyclic AMP levels were measured in DADLE-
treated hearts. Decreased levels of cyclic AMP were found at the start of the regional
ischaemie period (p < 0.001 vs controls). This group thus suggested that delta-opioid
receptor activity mediated protection may be associated with a reduction of tissue
cyclic AMP levels. Recently Genade et al (2001) also showed that DADLE elicited
cardioprotection in rats. In contrast to Aitchison et al (2000), DADLE administered as
a trigger i.e., 3 x 5 minutes and washed out before sustained ischaemia had no
effect. However, if administered 10 minutes before sustained ischaemia, it increased
functional recovery during reperfusion, suggesting a mediator effect for opioids. The
differences in experimental findings were attributed to the use of different models
(regional ischaemia in the work by Aitchison et ai, working heart model in the case of
Genade et al).
1.2.2.1.4 Endogenous catecholamines and prostaglandins
Asimakis et al (1994) were the first to show that preconditioning with noradrenaline
(an a and ïs-adrenerqic receptor agonist) and isoproterenol (a f1-adrenergic receptor
agonist) afforded significant protection in the isolated rat heart. They also showed
that propanolol, a non-selective f1-adrenergic receptor blocker, prevented the
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8cardioprotective effects of both these agents. This was confirmed by Miyawaki et al
(1997a) who showed that isoproterenol provided significant protection against
ischaemic myocardial injury by increasing functional recovery and tissue ATP
together with a decrease in lactate dehydrogenase (LDH) release in isolated rat
hearts. Yabe et al (1998) also showed that preconditioning elicited by ~-adrenergic
receptor stimulation with isoproterenol increased functional recovery and decreased
creatine kinase release during sustained ischaemia. Furthermore, since
cardioprotection was abolished by the treatment of polymixin, a protein kinase C
(PKC) inhibitor, they suggested that ~-adrenergic receptor stimulated preconditioning
was PKC mediated. Lochner et al (1999) have provided proof that the protection
elicited by a multi-cycle PC protocol may be partially dependent on the activation of
the Is-adrenerqic signaling pathway, since ïs-adrenerqlc receptor stimulated
preconditioning could be partially blocked by alprenolol, a fs-adrenerqic receptor
blocker.
Blockade of cyclooxygenase by aspirin in rats (Li et al 1992b) or rabbits (Liu GS et al
1992) did not interfere with the infarct size reduction achieved by IPC, suggesting
that endogenous prostaglandins were not involved in preconditioning's protection.
1.2.2.2 Receptor-independent triggers
These include (i) free radicals, (ii) nitric oxide (NO), and (iii) calcium.
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91.2.2.2.1 Free radicals
Mitochondrial respiration and oxidative phosphorylation are gradually uncoupled
during hypoxia or ischaemia/reperfusion (Lesnefsky et al 1997, Van den Hoek et al
1998). An immediate consequence of such gradual impairment of respiratory function
is the increase in the production of reactive oxygen species and free radicals in the
mitochondria (Van den Hoek et al 1998), and at high concentrations these alter the
integrity and increase the fluidity and permeability of cell membranes. Free radicals
can act as triggers of ischaemie preconditioning.
Infusion of N-2-mercaptopropionyl glycine (MPG), a cell-permeable radical
scavenger, completely abolished protection by IPC in rabbit hearts (Baines et al
1997). The mechanism by which oxygen radicals precondition the myocardium is less
clear, but free radicals can activate G-proteins (Nishida et al 2000), protein kinases
(Das et al 1999b), and ATP-dependent potassium channels (Bhatnagar et al 1990,
Jabr et al 1993, Tokube et al 1996).
In a review by Das et al (1999a), a vital role for the reactive oxygen species
generated during preconditioning in mediating cellular responses through diverse
intracellular and extracellular ligands was suggested. The following sequence of
events was proposed: Stimulation of protein phosphorylation by oxygen free radicals
appears to be a feasible mechanism for subsequent signal transduction leading to
the activation of the transcription factor NFKB. Activation of NFKB seems to be
regulated by the mitogen-activated protein kinases (MAPK). However, the exact
mechanism whereby oxygen radicals participate in signal transduction pathways is
not yet clear.
UNIVERSITEIT STELLENBOSCH
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1.2.2.2.2 Nitric Oxide (NO)
Nakano et al (2000a) and Post et al (2000) in rabbits and pigs respectively, have
provided evidence that NO is neither a trigger nor a mediator of the early phase of
ischaemie preconditioning against infarction. NO does however play an important role
in the second window of preconditioning (see later). Lochner et al (2000) however,
found evidence for a role for NO as a trigger in early/classical preconditioning in rat
hearts. In the latter work, pharmacological elevation of tissue cGMP levels by the NO
donors S-nitroso-N-pencillamine (SNAP) or sodium nitroprusside (SNP) before
sustained ischaemia i.e., as a trigger, elicited functional improvement during
reperfusion comparable to that achieved by PC. Administration of the NO synthase
inhibitors e.g., (N(omega)-nitro-L-arginine methyl ester or N-nitro-L-arginine) before
and during the PC protocol partially attenuated functional recovery, while they had no
effect when given after the ischaemic PC protocol or before sustained ischaemia
only. Therefore, it was concluded by this group that NO released during an ischaemic
preconditioning protocol acted as a trigger of classic preconditioning.
1.2.2.2.3 Calcium
Ashraf et al (1994) showed that calcium preconditioning, i.e., repetitive calcium
depletion and repletion for short durations, conferred cardioprotection against
ischaemia/reperfusion injury via the activation of PKC (Miyawaki et al 1996).
Miyawaki et al (1997b) showed, in Langendorff-perfused rat hearts, that a transient
increase in intracellular free calcium during IPC was an important trigger for the
activation of PKC, which was responsible for cardioprotection. The method employed
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to raise the intracellular calcium as a trigger was called hiqh-Ca'" preconditioning
(HCPC) i.e., 5 min perfusion of higher Ca2+ perfusate (2.3 mM Ca2+) followed by 10
min perfusion of normal perfusate (1.8 mM Ca2+). The IPC protocol consisted of a
single cycle of 5 min ischaemia and 10 minutes reperfusion. This was followed by
exposure to 40 min global ischaemia and 30 min reperfusion.
Furthermore the administration of chelerythrine, a PKC inhibitor, for 10 min before
and after the preconditioning ischaemia completely abolished the cardioprotection
induced by both IPC and HCPC. A significant increase in functional recovery and a
decrease in lactate dehydrogenase release in both IPC and HCPC hearts compared
with the Non-PC hearts were observed. This group concluded that a transient
increase in intracellular calcium during IPC was an important trigger for the activation
of PKC, which was responsible for cardioprotection. Work done by Cain et al (2000)
suggested that the flux of calcium through the L-type calcium channels acted as a
trigger of IPC, since atrial muscle taken from patients with chronic blockade of L-type
calcium channels could not be preconditioned by ischaemia (Cain et al 2000).
However, the calcium antagonist nisoldipine does not decrease IPC in an in situ
model of regional ischaemia in anaesthetised pigs, thereby challenging a major role
for endogenous calcium as a trigger of ischaemie preconditioning in vivo (Wallbridge
et al 1996). The role of endogenous calcium as a trigger of ischaemic preconditioning
requires further study.
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1.2.3 Signal transduction pathways
1.2.3.1 G proteins
Guanine nucleotide-binding regulatory proteins (G proteins) playa major role in the
regulation of a number of physiological processes. Myocardial ischaemia could
induce the changes in the receptor-G protein signal transduction system in the heart.
The activity of the Gs protein has been found to decrease with ischaemia and
reperfusion (Ohyanagi et al 1996).
Ravingerova et al (1995) showed, in isolated Langendorff-perfused rat hearts, that
PC led to a reduction of stimulatory Gs proteins, whereas inhibitory Gi proteins were
increased. Furthermore, Thornton et al (1993b) found that chronic treatment with
pertussis toxin blocks Gi proteins and abolishes preconditioning's protection in the
rabbit. Adenosine (Downey et al 1993) and opioid receptors (Schultz et al 1998) are
coupled to Gi proteins. The adenosine receptor is coupled through Gi to, amongst
others, phospholipases C (PLC) and 0 (PLO). PLC is responsible for the formation of
diacylglycerol (DAG), which in turns stimulates the translocation and activation of
PKC. Increased PLO activity accompanies preconditioning and PLO blockade with
high-dose propranolol attenuates its protection (Cohen et al 1996). Thus both
pathways are thought to be critical components of PKC activation which is involved in
PC.
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1.2.3.2 Protein kinase C (PKC)
The activation of PKC is regarded as very important in ischaemie preconditioning
(Speechly-Dick 1994, Ytrehus et al 1994). PKC catalyses the transfer of the 't:
terminal phosphate from ATP to the hydroxyl group of serine and/or threonine
residues in various protein substrates and this process is considered to be a
fundamental regulatory mechanism involved in cellular growth, differentiation and
immediate regulation of effector functions (Sugden et al 1995). The PKC family
consists of 12 serine/threosine kinases and can be classified into three distinctive
subfamilies. The subfamily of classical PKC isoforms includes PKCa, P1, P2 and yand
requires both calcium ions and lipids (i.e., phosphatidylserine, PMA and/or
diacylglycerol (DAG)) for their activation.
The subfamily of novel PKC isoforms which includes PKC<5,e, 11,~ and J.l do not
require calcium but still require lipids for their activation. The subfamily of atypical
PKC isoforms includes PKCs, t and A requires phosphatidylserine for its activity, but
neither calcium, nor DAG and/or PMA are required for its activation. In adult rat
hearts, novel PKCc and <5are the two major isoforms while the minor PKC isoforms
are represented by novel PKC11and atypical PKCt and s (Bogoyevitch et al 1993,
Mitchell et al 1995).
PKC activation and subsequent translocation to membrane compartments is a key
event in the PKC-dependent signaling cascade and is preceded by agonist-mediated
stimulation of receptor-associated phospholipase C (PLC). PLC, upon stimulation,
cleaves inositol-1.4,5-triphosphate and DAG from the membrane-bound
phosphatidylinositol moiety. DAG acts as a hydrophobic factor and increases the
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affinity of PKC to the membrane-integrated structures within the subcellular
compartments (Newton 1995).
PKC has been implicated as a key signal transduction step in one of the most
popular hypotheses (the so called 'PKC hypothesis' Simkhovich et al (1998)) which
requires the translocation of PKC from the cytosol to the sarcolemma and
subsequent phosphorylation of an as-yet unknown protein target as key events in
cardioprotection. Speechly-Dick and colleagues (1994) showed that in the in vivo
ischaemia model of the rat heart, the PKC inhibitor chelerythrine, when administered
after a preconditioning stimulus (i.e., prior to sustained ischaemia), abolished
protection conferred by IPC and caused an increase in infarct size.
Li et al (1995) found that in the rat heart the PKC inhibitor, calphostin C, also
abolished the protective effects when administered before the IPC protocol and
before the onset of sustained coronary occlusion. These studies may be considered
as positive or consistent with the 'PKC hypothesis' of preconditioning. In the isolated
rat heart model of regional ischaemia, confirmatory results have been reported by
Bugge and colleagues (1995) who found that the PKC antagonists polymyxin Band
chelerythrine blocked the protective effects of IPC. There appears to be data
obtained in the isolated rat heart subjected to sustained ischaemia and reperfusion
supporting the PKC hypothesis. Mitchell et al (1995), suggested that PKC activation
is central to protection by IPC by showing that PKC inhibitors, chelerythrine and
staurosporine, block the protection of IPC when administered before the IPC protocol
and washed out before sustained ischaemia. A study performed by Hu and
colleagues (1995) showed that pre-treatment with PKC inhibitors H-7 and
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bisindolylmaleimide blocked IPC while the PKC activator, PMA, mimicked its
protective effect.
While the studies mentioned above are considered positive, there are also negative
studies using the isolated rat heart model. Galinanes et al (1995), using
immunoblotting, were not able to demonstrate translocation of PKC8 and PKCE in the
isolated rat heart preconditioned with two brief episodes of ischaemia and
reperfusion. Moolman et al (1996a) reported that PKC inhibitors, chelerythrine and
bisindolylmaleimide, given either during the IPC protocol or before the onset of
ischaemia, did not abolish the protective effect of IPC in the globally ischaemie rat
heart. Moreover, the PKC inhibitors were also unable to block the reduction in lactate
accumulation caused by IPC. Thus the conclusion reached by these authors is that
PKC may not be involved in the mechanism of IPC in the rat.
The protective phenomenon of IPC has been unequivocally demonstrated in rats,
rabbits, dogs and pigs. In contrast, the role of PKC in this protection is controversial
in all of these species. It is important to remember that most of the results in support
of the PKC hypothesis were obtained using pharmacological approaches i.e., by
administration of PKC inhibitors and/or activators. The disadvantages of this strategy
(see review by Brooks et al 1996) include amongst other things, that almost every
inhibitor has ancillary effects and, for some, their specificity and selectivity are
questionable. Unfortunately, the same objection is also applicable to all currently
available inhibitors.
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Recently the isoforms of PKC have been receiving more attention. Several isoforms
of PKC i.e., epsilon, delta, and eta have been suggested as mediators of
preconditioning (Kawamura et al 1998, Ping et al 1997). Activation of PKC epsilon
has been shown to playa critical role in preconditioning to limit necrosis in cultured
neonatal rat ventricular myocytes (Gray et al 1997) and in anaesthetised rats
(Mitchell et a11995, Mochly-Rosen et aI2000). Ping et al (1997) also showed that the
activation and translocation of PKC epsilon isoform-mediated preconditioning
reduces cardiomyocyte necrosis in conscious rabbits. Lui et al (2001) found that PKC
epsilon was selectively activated in IPC and suggested that it was this isoform that
attenuates necrosis and apoptosis in isolated cultured chick cardiomyocytes.
The emergence of a role for certain PKC isoforms in preconditioning offers more
selective avenues to explore the role of PKC within a particular species and model. It
also gives rise to a need for biochemical isoform-specific assays, which would allow
quantification of selective PKC isoforms in different subcellular compartments. These
assays would also shed more light on the differences in isoform activity and
subcellular distribution within different species, models and protocols and the role
they play in cardioprotection elicited by preconditioning.
1.2.3.3 cAMP
As discussed above, Asimakis et al (1994) and Miyawaki et al (1997b) earlier showed
that ~-adrenergic receptor stimulation could elicit pharmacological preconditioning.
The signal transduction pathway of ~-adrenergic receptor activation is known, namely
that stimulation of the ~-adrenergic receptor, coupled to Gs protein, by isoproterenol
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activates Gsa to stimulate the production of cAMP via activation of adenylate cyclase
(Fleming et al 1992) which in turn activates cAMP to activate PKA (Campbell et al
1995). The question is what the relative role of each of the components of the p-
adrenergic receptor signal transduction pathway is in eliciting protection.
Furthermore, it was not known whether the p-adrenergic receptor pathway was
involved in ischaemic preconditioning.
Ischaemia releases catecholamines (specifically noradrenaline) from the nerve
terminals of the sympathetic nervous system in the myocardium (Schëmig et al
1984). Upon its release, noradrenaline could activate the a1-adrenergic receptor,
which is coupled to the PKC pathway. The involvement of PKC activation in IPC was
discussed earlier. Lochner et al (1999) investigated the role of endogenous release
of catecholamines and activation of the p-adrenergic receptor in IPC. First they
showed that a multi-cycle IPC protocol is characterised by cyclic increases in tissue
cAMP levels. By using reserpine (injected intraperitoneally), that depletes
endogenous catecholamine stores, they were able to abolish cAMP generation
during the IPC protocol. These findings suggest that that the release of endogenous
catecholamines is mainly responsible for the cyclic increases in tissue cAMP and
thus PKA activation during preconditioning.
The question whether this endogenous activation of the p-adrenergic receptor and
concomitant increase in cAMP played a role in the triggering of PC was then
investigated. The same group (Lochner et al 2000) found that administration of the p-
adrenergic receptor alprenolol during the triggering phase partially abolished the
protection of a multi-cycle (3 x 5 min ischaemia) preconditioning protocol, thereby
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proving the involvement of ~-adrenergic stimulation in the triggering pathway of
ischaemie preconditioning.
lt was also observed by Moolman et al (1995) and Sandhu et al (1997) that
preconditioned hearts had a significantly lower cAMP content at the end of sustained
ischaemia. The next question was whether this had mechanistic importance. Sandhu
et al (1996) found that infusion of NKH477 (which increases cAMP) immediately prior
to sustained ischaemia did not have an effect on infarct size in multi-cycle
preconditioning, but partially abolished the protection of a single cycle ischaemie
preconditioning. Moolman et al (1996b) also could not demonstrate any reduction in
functional recovery when attempting to increase cAMP in preconditioned hearts by
perfusion with forskolin immediately prior to sustained ischaemia.
These experimental findings indicate that the activation of the ~-adrenergic receptor
during the trigger phase of IPC is important for the mechanism of preconditioning, but
that cAMP has a role as mediator only under specific experimental conditions. The
role of PKA in this cascade is not yet clear.
1.2.3.4 Tyrosine kinases
The potential role of protein tyrosine kinases in PC were first suggested by Maulik et
al (1996), who showed that IPC induced an alteration in the tyrosine phosphorylation
profile of several cardiac proteins. The receptor-dependent endogenous triggers,
such as adenosine, bradykinin, and endogenous opioids all couple through
phospholipases to activate protein kinase C, which in turn activates a tyrosine kinase
(Downey et al 1997). Baines et al (1998) have also suggested that the tyrosine
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kinase is downstream of PKC, but in addition, that the tyrosine kinase may be a MAP
kinase kinase. Fryer et al (1998) suggested that activation of a tyrosine kinase is
involved as a trigger and not as a mediator of IPC in the rat myocardium as assessed
by infarct size. Further work by this group (Fryer et al 1999a) suggested that the
efficacy of tyrosine kinase and PKC inhibition to block IPC depends on the intensity
of the preconditioning stimulus and that these kinases may work through parallel
pathways.
Kitakaze et al (2000) however by using genistein, a tyrosine kinase inhibitor, have
shown that tyrosine kinase does not trigger the infarct size-limiting effect of the early
phase of IPC in canine hearts. Conflicting data and various pathways make the role
of tyrosine kinases in preconditioning unclear. Further investigation is required to fully
understand its role in preconditioning.
1.2.3.5 Mitogen-activated protein kinases (MAPK)
Potential downstream targets of PKC, PKA, and tyrosine kinases are the mitogen-
activated protein kinases (MAPK). Three major divisions of the MAP kinase family
exist in the heart: extracellular signal-regulated kinases (ERK's); c-Jun N-terminal
kinases (JNK's), and p38 MAPK's (Sugden et al 1998). MAPK's are considered to be
primary mediators of the myocyte stress response (Sugden et al 1998), thus
implicating a role for MAP kinases in IPC. Available data suggest a role for all these
MAP kinases in preconditioning (see below).
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1.2.3.5.1 ERK
The role of ERK in the stress response to ischaemia and in PC is still under
investigation. Ping et al (1999a) showed in conscious rabbits that ischaemic
preconditioning induces a rapid activation of ERK1 and ERK2. An inhibitor of ERK
(PO 98059) when administered during ischaemia i.e., as a mediator, fails to dose-
dependently block the infarct size reduction seen after IPC in the isolated rabbit heart
(Kim et al 1999), and its intramyocardial infusion abolishes IPC's protection in pigs in
vivo (Strohm et al 2000). Mocanu and colleagues (2002) showed, in the isolated
perfused rat heart, that when PO 98059 was administered during a multi-cycle IPC
protocol, it had no significant effect upon infarct size reduction when compared to the
IPC hearts, thus suggesting no role for ERK as a trigger.
The cytoprotective property of ERK was also demonstrated outside the field of
ischaemic preconditioning. Baxter et al (2001) examined the effects of transforming
growth factor-beta 1 (TGF-beta 1) on reperfusion injury and assessed the role of
ERK1 and ERK2 in rat ventricular myocytes subjected to hypoxia and reoxygenation.
Incubation with TGF-beta 1 transiently activated ERK1 and ERK2 in normoxic
myocytes. Intact hearts that received TGF-beta 1 during reperfusion showed a
significantly smaller infarct size (p < 0.01). PO 98059 abrogated this protective effect
and these studies suggest that TGF-beta 1 decreases cardiac myocyte apoptosis
during early reperfusion and limits infarct size through ERK1 and ERK2 activation.
This has led to the formulation of the so-called "growth factor hypothesis of cardiac
protection", which states that growth factors acting through ERK activation serve as
general protective agents against myocardial stress.
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1.2.3.5.2 JNK
The JNK family consists of at least 2 isofarms, the 46-kDa JNK1 and the 54-kDa
JNK2, both of which are present in the heart and are strongly activated during
reperfusion following ischaemia (Clerk et al 1998). Ping et al (1999a) showed that
JNK1 and JNK2 activities are significantly increased after the IPC protocol.
JNK1 activation during no-flow ischaemia is most likely mediated by PKC, since
activation of JNK1 is completely inhibited by chelerythrine, a PKC inhibitor (Ping et al
1999a). In isolated rat hearts, inhibition of JNK2 with curcumin abolishes the infarct
size reduction of IPC to a similar extent as blockade of p38 MAPK using SB 203580
(both agents were administered before the IPC protocol) (Sato et al 2000). This
would suggest that JNK has a role to play in PC. Further experimental evidence to
support such a triggering role for JNK is however still lacking at this stage.
1.2.3.5.3 p38 MAPK
The role of the p38 MAPK signalling pathway has been extensively investigated but
remains controversial. Whether an IPC protocol causes p38 MAPK activation, and
whether inhibition of p38 MAPK blocks the cardioprotective effects of PC, lie at the
heart of the controversy. At least 4 isoforms (a, ~, y, 8) of p38 MAPK have been
identified (Sugden et al 1998) and it is known that different isoforms of p38 MAPK
mediate different biological functions (Michel et al 2001). However it would appear
that only the p38a and p38~ isoforms are expressed to any degree in the heart
(Sugden et al 1998). In neonatal rat card iomyocytes , p38a mediates apoptosis
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whereas p38p is anti-apoptotic (Wang et al 1998). These different isoforms with
different actions may contribute to the controversies surrounding the role of p38
MAPK.
Weinbrenner et al (1997) showed that a short period of ischaemia (5 minutes) did not
activate p38 MAPK in rabbit heart. In contrast, others (Bolli et al 1988, Marais et al
2001 a, Przyklenk et al 1988) have found that ischaemia causes p38 MAPK activation
within 5 minutes. However, its activation during a multi-cycle PC protocol is transient
and wanes after exposure to 3 episodes of ischaemia. This does not preclude a role
as a trigger, since its activation may set into motion a series of signal transduction
events that may eventually lead to protection.
SB 203580, a recently developed selective inhibitor of p38 MAPK (Cuenda et al
1995) has been used extensively. Unfortunately the results obtained have been
confusing, party due to the fact that its effect is dose-dependent - at doses below 10
!JM it selectively inhibits p38 MAPK, but at higher doses, it also inhibits JNKs.
1.2.3.5.3.1 p38 MAPK as a mediator of protection
Armstrong et al (1999) reported in isolated rabbit cardiomyocytes that SB 203580
promoted injury in non-preconditioned cells. SB 203580 did not affect infarct size in
isolated rat hearts (Mocanu et al 2000) or rabbit hearts (Nakano et al 2000b). In
contrast, data from our own laboratory shows that administration of SB 203580
protected the heart against damage (Marais et al 2001 a).
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1.2.3.5.3.2 p38 MAPK as a trigger of protection
When SB 203580 was administered before the IPC protocol, it blocked the protection
of IPC observed as an abolishment of reduced fragility (Weinbrenner et al 1997) in
isolated rabbit cardiomyocytes. Similarly, Mocanu et al (2000) showed in isolated
rabbit hearts that SB 203580 completely blocked the protection afforded by
preconditioning. In contrast, Sanada et al (2001) demonstrated a reduction in infarct
size in dog hearts, while Schneider et al (2001) (in isolated rat hearts) and Barancik
et al (2000) (using pig hearts in vivo) demonstrated that p38 MAPK inhibition did not
abolish the infarct size reduction of IPC, and even reduced infarct per se.
Reasons for conflicting results may be due to differing experimental models and
animal species. These range from isolated perfused rabbit hearts (Nakano et al
2000c), rat heart (Maulik et al 1998, Schneider et al 1999), and pig hearts (Barancik
et al 2000, Behrends et al 2000), to cultured cardiac cells (Armstrong et al 1999,
Saurin et al 1999) and biopsy tissue samples from human hearts. It could also be due
to the differences in p38 MAPK isoforms and also the selectivity of inhibitors for these
isoforms. Different protocols, not distinguishing between triggers and mediators add
to the confusion.
Further downstream events from p38 MAPK have received little attention thus far,
except for heat shock protein 27 (HSP27). The primary substrate of p38 MAPK is
MAPK-activated protein kinase 2 (MAPKAPK-2) which phosphorylates the small (27-
kDa) heat shock protein HSP27 (Freshney et al 1994), an important regulator of actin
dynamics. The phosphorylated HSP27 promotes polymerisation of actin filaments,
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thus increasing the stability of the cytoskeleton (Guay et al 1997). Over expression of
HSP27 in isolated rat myocytes confers protection against simulated ischaemia,
whereas depletion exacerbates injury (Martin et al 1997). Because prolonged
ischaemia is known to cause cytoskeletal disruption (Ganote et al 1993b), activation
of the p38 MAPKlHSP27 pathway could well contribute to the protective action of
ischaemie preconditioning by maintaining the integrity of the actin cytoskeleton.
1.2.4 Potential end-effectors of ischaemie preconditioning
These include energy and substrate metabolism, protein synthesis, the sodium-
proton exchanger, the cytoskeleton, volume regulation, tumour necrosis factor (TNF)-
a, and the most popular one, the KATP channels (Schulz et al 2001 b). In the following
section the focus will be on the KATP channels .
1.2.4.1 .tSATP channels
The nature of the end-effector(s) ultimately activated by ischaemie preconditioning
has been very elusive. Considerable evidence suggests that opening of KATP
channels represents the final step in protective signal transduction processes. The
KATP channel is composed of two subunits: the channel protein itself, which belongs
to the inward-rectifier K+ channel family, and the sulfonylurea receptor, a member of
the ATP-binding cassette superfamily, which is involved in the binding of ATP and
sulfonyl compounds (Trapp et al 1997, Aguilar-Bryan et al 1998). Both subunits are
absolutely required for channel activity and are associated with a 1:1 stoichiometry.
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It is important to point out that there two kinds of KATPchannels i.e., sarcolemmal and
mitochondrial. The initial studies focussed on sarcolemmal KATPchannels.
Much of the evidence supporting the KATPhypothesis is based on the blockade of the
protective effects of both IPC and pharmacological PC by inhibitors of the KATP
channels (Grover et al 1997). Auchampach and colleagues (1992), and Gross and
colleagues (1992) have shown that the KATPchannel is important for preconditioning
in the canine model. Intravenous glibenclamide, a KATPchannel antagonist, abolished
the protective effect afforded by preconditioning in reducing infarct size in the canine
model (Gross et al 1992). However, there have also been discrepancies in the results
obtained. In studies with dog hearts (Baxter et al 1997, Yao et al 1993), pre-
treatment with diazoxide, a mitochondrial KATP channel agonist protected the
myocardium from ischaemia, while in another study in rabbits, diazoxide failed to
reduce the infarct size (Baxter et al 1997). In addition, Grover et al (1995) and Yao et
al (1994) found that direct activation of the KATPchannels with bimakalim and
cromakalin respectively before ischaemia reduced infarct size. In rabbit hearts,
isolated rabbit cardiomyocytes and rats, the importance of KATP channels in
preconditioning has not been confirmed (Liu Y et al 1992, Thornton et al 1993a). To
explain the salutatory effect of these KATPchannels, it was originally proposed that
opening of the sarcolemmal channels caused shortening of the myocardial action
potential duration, which could in turn exert a cardioplegic action (Grover 1997).
The discovery that KATPchannels are present in mitochondrial membranes (Garlid et
al 1996, Inoue et al 1991) opened a debate as to the relative contribution of
sarcolemmal vs mitochondrial KATP(mKATP)channels in the myocardial protection
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afforded by PC (Baines et al 1999, Gross et al 1999). Recent evidence, however,
suggests that the mitochondrial KATP channel, rather than its sarcolemmal
counterpart, mediate protection. Garlid et al (1997) demonstrated that diazoxide was
2000-fold more selective for opening mitochondrial channels than sarcolemmal KATP
channels in the heart. Furthermore, 5-hydroxydecanoate (5-HD), a specific inhibitor
of mKATP channel, inhibited the protection afforded with diazoxide. A similar
protective effect with diazoxide, and reversal with 5-HD, was found in a myocyte
model of hypoxic cell injury (Liu et al 1998). Diazoxide was subsequently used
extensively in studies to elucidate the significance of the mKATP channel in
preconditioning.
Part of unravelling the PC phenomenon is to establish how preceding signal
transduction pathways can be linked to the KATPchannels. Many studies suggest a
role for PKC: Armstrong et al (1995) observed in isolated rabbit cardiomyocytes that
the phorbol ester PMA potentiates the opening of the KATPchannels by pinacidil when
ATP levels are reduced by metabolic inhibition with potassium cyanide. They also
reported that adenosine has little effect on myocytes in the basal state but it opens
KATPchannels after pre-treatment with PMA, which suggests that PKC participates in
opening of the channels. Therefore, opening of the KATP channels during
preconditioning may require both the phosphorylation by PKC or another kinase and
the presence of adenosine or another G protein-coupled agonist. Kirsch et al (1990)
reported that Gi released by stimulated adenosine A1 receptors opens KATPchannels
directly. In that study, other G protein subunits also affected KATP channel
conductance. The direct gating of a KATPchannel has previously been demonstrated
in heart tissue (Ito et al 1992) and may contribute to the mechanism of protection.
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It is not clear why opening of the ATP-sensitive K+ channels is cardioprotective. In
addition it is still not conclusively proven that the KATP channel is indeed the end
effector. Further investigation should therefore continue until the end effector has
been identified.
1.2.5 Second Window of Preconditioning (SWOP)
Ischaemie preconditioning has been found to be biphasic, with an early or classical
phase and a second window of preconditioning (SWOP), or late/delayed phase of
protection. The early phase of PC develops from the initial ischaemie insults and is
relatively short-lived (2-3 hours), while SWOP appears 12-24 hours later and lasts for
3-4 days (Kuzuya et al 1993, Marber et al 1993). SWOP's cardioprotective effects
have been observed in open chest rabbit and dog and chronically instrumented
conscious rabbit and rat (Kuzuya et al 1993, Marber et al 1993, Speechly-Dick et al
1994, Yellon et al 1995). Although early/classical PC and SWOP share many of the
same signal transduction pathways, there are differences between both phenomena
e.g., both early PC and SWOP limit infarct size but the infarct-reducing effects of
early PC are more robust (Cohen et al 2000, Kuzuya et al 1993, Marber et al 1993,
Murry et al 1986). SWOP however attenuates myocardial stunning, whereas early PC
does not (Bolli 1996). The signalling pathway whereby NO (either endogenous or
exogenous) induces late PC involves the generation of reactive oxygen species
(Takano et al 1998) and the activation of the epsilon isotype of PKC (Ping et al
1999b, Vondriska et al 2001). It also involves the subsequent recruitment of Src and
Lek tyrosine kinases (Dawn et al 1999, Vondriska et al 2001) and the activation of
transcription factor NFKB (Xuan et al 1999), culminating in the transcriptional
activation of iNOS gene (Jones et aI1999).
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The most important difference is that SWOP's cardioprotection results from activation
of genes and expression of new protective proteins. It is unlikely that expression of
new proteins playa role in the early protection after IPC, and therefore it is possible
that an entirely different set of triggers and signalling pathways are important to
SWOP (Kloner et al 1998). Salutatory effects can be achieved with exogenous NO,
either by NO-releasing agents or NO precursors (Bolli et al 2001). In addition, NO
has been found to playa critical bifunctional role (as a trigger and a mediator) in late
PC, a paradigm referred to as the NO hypothesis of late PC (Bolli et al 1998).
Specifically, enhanced generation of NO by eNOS is essential to trigger the late
phase of ischaemia-induced and exercise-induced PC. Enhanced production of NO
by iNOS, recently suggested to be a hypoxia-inducible protein, is obligatorily required
to mediate the anti-stunning and anti-infarct actions of late PC induced by five
different stimuli (ischaemia, adenosine A1 agonists, opioid U1 agonists, endotoxin
derivatives, and exercise). The NO hypothesis of late PC has thus revealed a
previously unrecognised cytoprotective function of iNOS in the cardiovascular system
(Bolli 2001 ).
The identification of the cellular basis of PC should provide a conceptual framework
for developing new therapeutic strategies aimed at mimicking the cardioprotective
effects of late PC. This can be achieved with pharmacological agents (e.g. PC-
mimetic agents), or genetic approaches (e.g. transfer of cardioprotective genes), that
can maintain the heart in a sustained or chronic defensive (preconditioned) state
(Bolli et al 2000).
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1.2.6 The endpoints of preconditioning
1.2.6.1 Contractile function
Contractile recovery is often used as an endpoint in the study of ischaemic
preconditioning. Although it appears logical that a reduction in infarct size should
result in improved contractile function during reperfusion, regional function is often
not improved within the first hours of reperfusion (Cohen et al 1999, Jenkins et al
1995). However with longer periods of reperfusion, functional recovery may ensue.
Therefore a lack of functional recovery does not necessarily refute the morphological
protection induced by prior preconditioning, while caution should also be exercised
when extrapolating from functional recovery to a reduction in infarct size. In addition
to the above, it appears as if the perfusion model may also influence the outcome of
the results - retrogradely perfused hearts (without afterioad) recover functionally to a
larger extent than working hearts that have to work against an afterload (Lochner,
unpublished observations).
1.2.6.2 Oncosis/necrosis or infarct size
Cell death in ischaemia may occur by two different mechanisms: oncosis or
"accidental" cell death, and apoptosis or "suicidal" cell death. Necrosis is commonly
used but is not appropriate, because it does not indicate a form of cell death but
refers to changes secondary to cell death by any mechanism, including apoptosis
(Majno et al 1995). Because ischaemie cell death (in known models) is accompanied
by swelling, the name oncosis was proposed for this condition. Oncosis is derived
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from onkos, meaning swelling, which leads to necrosis with karyolysis. To avoid
confusion and for the sake of convenience, it was decided to make use of the
conventional term "necrosis" as the form of cell death opposed to apoptosis.
Necrosis is characterized by depletion of intracellular ATP, cellular swelling,
disruption of organelles, and plasma membrane disruption, followed by an
inflammatory reaction which removes the injured cells (Dipsersyn et al 2001).
Although cleavage of DNA strands may occur late in the terminal evolution of cell
necrosis (Gold et al 1994), the afore-mentioned cellular damage characteristically
precedes it (Arends et al 1990). Necrosis develops only minimally during ischaemia
and is detected mainly during reperfusion (Ganote et al 1993a, Hu et al 1995, Li et al
1993, Van den Hoek et a11996, Yao et a11999, Zhang et aI2000).
1.2.6.2.1 Techniques for necrosis detection
Triphenyl tetrazolium chloride staining (TTC) has facilitated the macroscopic
identification of myocardial infarction. This method has been shown to be sensitive
and specific for myocardial necrosis (Gallagher et al 1980) and thus it is possible to
distinguish necrotic from viable myocardium (Vivaldi et al 1985). Tetrazolium dyes
form coloured precipitates in the presence of intact dehydrogenase enzyme systems.
Areas of necrosis lack dehydrogenase activity and therefore fail to stain. Areas of
necrosis are therefore distinguishable and thus quantifiable by using computerised
planimetry. At the end of the experiments, hearts are injected with Evan's Blue dye to
colour the in vivo area at risk. They are then excised, cut into transverse slices and
stained with TTC. The method of TIC staining for the determination of infarct size
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and area at risk has been used extensively in rats (Wolfe et al 1993), dogs (Fishbein
et al 1981), pigs (Freeman et al 1990), and cats (Brunvand et al 1995). Also in the
study of both classic and late PC, infarct size measurement has been the preferred
endpoint by many workers (for example Downey and colleagues, Yellen et al).
1.2.6.2.2 Measure of viability
In the intact heart, the effect of myocardial injury and the protective actions of
endogenous or exogenous agents and mechanisms have primarily been investigated
with regard to physiological changes e.g., functional recovery during reperfusion after
ischaemia. In isolated cardiomyocytes, the effects of cell injury on the viability of
these cells, and the effect of cardioprotective agents on cellular survival have only
been partially addressed (Buerke et al 1994, Cheirif et al 1995, Ohata et al 1994).
Various assays exist to investigate cellular viability. "Lytic" viability assays, such as
the Trypan blue exclusion method or the lactate dehydrogenase release assay, rely
upon the integrity of the plasmalemma as indicator of cell viability (Isowa et al 1996,
Tollefson et al 1996). The trypan blue exclusion method works on the principle that
cells with intact plasma membranes will not take up the dye and thus be stained
yellow and often appear rod-shaped. Cells with compromised/lysed plasma
membranes will take up the dye and be stained blue. An assay, which reflects not
only cell membrane integrity but also cellular metabolic status, may be more
appropriate for cells with high-energy requirements (Gomez et al 1997).
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The MTT assay is such an assay, based upon the reduction of (3,4-5 dimethylthiazol-
2-yl)-2,5- diphenyl tetrazoliurn (Mn) bromide into formazan pigments (Buttke et al
1993, Mosmann 1983). Intracellularly, this reduction is predominantly dependent
upon mitochondrial reductase activity, and is carried out by catalytic reactions
coupled to the NADPH- and NADH-dependant redox systems (Ferrara et al 1993).
Changes in Mn reductase activity are detectable even before membrane lysis (Ni et
al 1996). Decline in enzyme activity (essential for electron transfer) as well as the
depletion of cofactors needed for redox reactions correlate with loss of cellular
viability. This makes the MTT reductase activity a refined marker of cell viability
(Carmichael et a11987, Roehm et al 1991, Tollefson et al 1996).
1.3 Apoptosis
1.3.1 General
For many years it has been believed that necrosis was the predominant form of
cardiomyocyte death following ischaemia and reperfusion. However, during the past
few years it has become clear that apoptosis plays a significant role in myocardial
ischaemia/reperfusion injury (Gottlieb et al 1994, Kajstura et al 1998). Ischaemic
preconditioning has also been shown to protect against apoptosis (see below).
1.3.2 Characteristics of cellular changes in apoptosis (Table 1.1)
Apoptosis is characterized by distinct morphologic alterations. There is profound
shrinkage and membrane blebbing, which is associated with externalization of
phosphatidylserine. Cytoskeletal architecture is altered by the proteolytic cleavage of
fodrin, actin, and of one or more G-proteins that regulate the state of assembly of the
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cytoskeleton (Rudel et al 1997). One of the most important aspects of apoptosis is
the preservation of an intact plasma membrane with expression of cell surface
markers for ingestion of a neighbouring cell or professional phagocyte to ingest the
cell. This serves to limit inflammation. It should be noted that these external features
are distinct from those seen in necrosis in which cell swelling results in rupture of the
plasma membrane which in turn causes an inflammatory reaction leading to removal
of these injured cells (Dispersyn et al 2001). Other features of apoptosis include
shrinkage of nuclei, condensed chromatin, intact mitochondria, the cleavage of
nucleosomal DNA into fragments of 185 base pairs whereas necrotic cells exhibit
irregular clumping of the chromatin, mitochondrial swelling and irregular nucleosomal
DNA. Another important difference is that apoptosis is energy-dependent (Eguchi et
al 1997) while necrosis is not. Energy is needed in apoptosis to start and keep the
apoptotic machinery operative while if the energy is depleted the cell will die by
necrosis.
Table 1.1: Cell death in ischaemia
Agogtosis Oncosisl necrosis
Cell volume shrinkage oedema
Chromatin condensation clumping
Mitochondria intact swelling
Cell membrane intact ruptured
Nucleosomal DNA cleaved 185 kB irregular
Inflammation no yes
ATP-dependent yes no
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1.3.3 Biochemical events associated with apoptosis (Figure 1.1)
One of the most central biochemical features of apoptosis is the activation of a class
of cysteine proteases known as caspases. Caspases are a group of cysteine
proteases that cleave protein substrates at the carboxyl side of aspartate residues
(Nicholson et al 1997). Cells possess multiple caspases, which may work in a
cascade fashion. They have a common structure, in which there is a prodomain of
variable length, followed by a region of -20 kD and a carboxyl terminal region of -10
kD. The three domains are separated by consensus caspase cleavage sites and the
inactive zymogens (pro-caspases) must be cleaved to between the 20 and 10 kD to
become active. The two fragments associate and form a heterotetramer that
represents the fully active enzyme.
Two pathways of caspase activation have been identified: one activated through a
cell surface signal leading to caspase activation, also known as the extrinsic pathway
or "death receptor pathway". The other pathway involves the mitochondria and is
hence known as the "mitochondrial pathway" (Borgers et al 2000, HaunsteUer et al
1998). The mitochondrial pathway seems to be more important in ischaemia!
reperfusion induced apoptosis. Both these pathways ultimately activate the
downstream (effector) caspases such as caspase-3, which leads to cleavage of
death substrates such as PARP, which in turn leads to DNA fragmentation and cell
death.
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Apoptosis through death signal
I death receptor pathway I
~
I mitochondrial pathway
I
Activation of downstream-caspases
I Caspase-3
Structural proteins eg. Lamin AlB DNA repair e.g., PARP
DNA frgmentation
CELL DEATH
Fig 1.1 Simplified version of the major events in the apoptotic cascade.
(Elsasser et al 2001)
1.3.3.1 The extrinsic/death receptor pathway
Cell-surface receptor-mediated mechanisms that control apoptosis act through a
signal transduction system that is the same for all activated receptor processes. It
involves the stimulation of the receptor, the activation of protein kinase/phosphatase
cascades, and the release of second messengers to upregulate or suppress the
transcription of specific genes.
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The best characterized pathways involve binding of a Fas ligand (FasL) and TNF-a
to their respective receptors (Fas and TNFR-1 respectively) (Nagata 1999). Binding
of the ligand to the receptor leads to intracellular association of proteins that interact
through a conserved region known as the death domain, one example of which is
FADD (Fas- associated death domain). FADD then recruits a specialized caspase
(caspase 8, also known as FLlCE) through a second domain (the death effector
domain), and the aggregated complex results in auto processing of caspase-B
molecules. The fully processed caspase-B is then free to interact with downstream
caspases such as caspase-3, as well as other targets such as the mitochondria
(Kuwana et al 1998). Many cellular stressors, such as DNA-damaging agents,
gamma irradiation, and pro-apoptotic cytokines such as TNF-a also activate acidic
and/or neutral sphingomyelinases to generate ceramide. Ceramide acts as an
intracellular signaling molecule to activate a kinase pathway that leads to apoptosis in
some settings and proliferation in others (Obeid et al 1993). Ceramide has also been
shown to playa role in TNF-a-mediated apoptosis in cultured cardiomyocytes (Krown
et aI1996).
Ultraviolet light, DNA-damaging agents, and oxidative stressors (e.g., hydrogen
peroxide) have also been shown to playa role in apoptosis via the JNK pathway in a
variety of systems (Johnson et al 1996). Hydrogen peroxide (H202) in particular has
been shown to induce TUNEL positivity, cytochrome c translocation, caspase-3
activation, PARP cleavage, and dissipation of the mitochondrial membrane potential
in cultured neonatal rat cardiac ventricular myocytes making it a particularly good
trigger of apoptosis as it activated all the relevant markers of apoptosis in this model.
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The intrinsic/mitochondrial pathway
It has become evident that multiple proteins of the huge BcI-2 family regulate
mitochondrial function. Pro-apoptotic factors such as Bax, Bak and Bid counteract
anti-apoptotic components such as BcI-XL resulting under physiological
circumstances in a balance in favour of protection from cell death and in preservation
of the mitochondrial permeability pore complex (PTP). Under stress conditions such
as ischaemia/reperfusion the PTP is disturbed and cytochrome c, AlF (apoptosis
inducing factor) and procaspase-9 are released from the intermembrane
mitochondrial space into the cytoplasm where Apaf-1 (apoptotic protease activation
factor) is activated. Apaf-1 interacts with cytochrome c and dATP to activate
caspase-9 (Li et al 1997). Caspase-9 then activates downstream caspases such as
caspase-3 and also protein kinases and phosphatases, which promote fragmentation
of DNA.
Once activated, caspase cleaves multiple targets. A widely recognized target is the
enzyme poly (ADP-ribose) polymerase (PARP). PARP is involved in DNA repair and
in the supervision of genome structure and integrity in stressed cells (Nicholson et al
1995). This enzyme recognizes single-strand DNA breaks and activates repair
enzymes by poly-ADP-ribosylating them. However, in the face of extensive DNA
damage, this enzyme can consume all the available NAD, which will lead to depletion
of cellular energy currency. Apoptosis requires energy (Eguchi et al 1997) and thus it
has been suggested that PARP cleavage, and thus inactivation, is essential for the
cell to retain enough energy to complete the apoptotic process. PARP cleavage can
therefore be utilized as a marker of apoptosis. Other targets include OFF (DNA
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fragmentation factor), an endonuclease responsible for degradation of the genome
during apoptosis (Liu et al 1997). DNase I and II are other endonucleases which
have been implicated. DNase I has been shown to cleave DNA into oligonucleosomal
multiples as seen in apoptosis (Peitsch 1993) and DNase II, as the intracellular pH
drops below 6.8, becomes active and can generate oligonucleosomal fragments.
These oligonucleosomal fragments are used as markers of apoptosis as detected
with the ELISA method or DNA laddering.
It can be seen that apoptosis activates a variety of enzymatic processes that serve to
degrade the genomic DNA, inactivate cellular enzymes that might facilitate cell
survival, deplete intracellular energy, and fragment the cell into smaller pieces for
easy removal.
1.3.4 Techniques for apoptosis detection
There are several techniques available to verify apoptosis in tissue samples each
technique however with its own problems. Apoptotic bodies are best viewed by
electron microscopy but apoptotic bodies, are however phagocytosed within hours
after cell death and it may therefore be difficult to verify whether apoptosis affects
only a limited number of cells or occurs transiently. Nuclear staining with the
fluorescent dye bisbenzamide (Hoechst 22358) allows for the visualization of nuclear
condensation and fragmentation in both cell culture and tissue sections. Separation
of cellular DNA in agarose gels shows a characteristic ladder-like pattern of
fragments with multiples of 200 bp in length. The disadvantage is assigning the
apoptotic process to one cell type whenever different cell populations are analyzed
as in whole tissue.
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The TUNEL (TdT-mediated dUTP nick end-labelling) technique is the most widely
used but it can also label non-apoptotic DNA fragmentation, and is therefore also the
most criticized method (Onoh et al 1998, Saraste et al 1997). ISEL (in situ end
labeling) is also commonly used. A technique, which employs the binding of Annexin
V to phosphatidylserine exposed on the cell membrane during apoptosis, has
recently been extensively employed as a reliable and quantifiable marker of
apoptosis (Clodi et al 2000, Hreniuk et al 2001, Rucker-Martin et al 1999). Detection
of protein fragments by Western blotting has also been used to verify cell death in
cell cultures of apoptosis.
Activation of execution caspases, such as caspase-3 (Kang et al 2000, Narayan et al
2001, Schaper 1999, Suzuki et al 2001) and specific cleavage of cellular target
proteins, such as PARP, are considered to be hallmarks of apoptosis (Lazebnik et al
1994, Nicholson et al 1995).
1.3.5 Role of MAP kinases in apoptosis
MAPK cascades contain at least three protein kinases that work in series and these
three enzymes comprise a module. The MAPK kinase kinase (MAPKKK) is activated
by a variety of stimuli, which commonly include mitogenic stimuli such as growth
factors and PMA in the case of the ERKs, or physiological stress such as
ischaemia/reperfusion and hypoxia in the case of JNK and p38 MAPK. These
kinases then phosphorylate and activate the MAPK kinase (MAPKK) or MAPK! ERK
kinases (MEKs) which in turn selectively activates ERK 1/2, p38, or JNK respectively.
Stellenbosch University http://scholar.sun.ac.za
40
It is well established that ERK, JNK, and p38 MAPKs are activated during cellular
stress. Whereas ERK activation by stress seems to protect against most stressors,
the exact role of JNK and p38 MAPK remains elusive. There are at least two
possibilities. These activated protein kinases may contribute to signal transduction
pathways that culminate in the cell death (i.e., necrosis and apoptosis) following
stress. Alternatively these MAPKs may also act to prevent widespread cell death,
limit damage, apoptosis or mediate adaptation.
1.3.5.1 Initiating cell death
It is well recognized that activation of p38 MAPK and JNK/SAPK are pro-apoptotic in
many situations (Obata et al 2000, Park et al 2000). Specific assessment of the role
of stress-activated MAPKs requires the use of specific chemical inhibitors,
overexpression of MAPKs, or transgenic approaches.
Specific inhibitors of p38a and p38p MAPKs, SB 203580 and SB 202190 have been
extensively used. Although SB 203580 has a potent effect on the activity of the p38a
and p38p MAPK, it's efficacy for p38y and p388 isoforms is low (Lee et al 1999).
Moreover, at a higher concentration (IC5o 5 urnol/l.), this compound will inhibit JNK
and phosphatidylinositol 3 (PI3) kinase/PKB (Lali et al 2000) both of which have been
shown to be recruited by IPC (Ping et al 1999a). The use of chemical inhibitors
suggests that the p38 MAPKs promote cardiac myocyte death during extended
periods of ischaemia or exposure to hydrogen peroxide (Mackay et al 1999, Meldrum
et al 1999). Studies using isolated perfused hearts conclude that p38 MAPK plays a
pivotal role in promoting myocardial apoptosis (Ma et al 1999). Cardiac injury in
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response to oxidative stress induced by hydrogen peroxide is apparently mediated by
a p38 MAPK-dependant production of TNF-a (Meldrum et al 1999). In view of this
detrimental role for p38 MAPK in apoptosis, cardioprotection may be correlated with
the ability of a compound or intervention to inhibit p38 MAPK activation.
The transgenic overexpression of MAPK pathway members has yielded more insight
into the relative importance of the p38 isoforms. Overexpression of their specific
activators, MKK3 and MKK6, indicates that this pathway also plays a complex role in
the cardiac myocyte. Whilst the overexpression of MKK3 or MKK6 increased cell
surface area, sarcomeric organisation and ANF expression, the co-expression of
MKK3 with p38a prevented these changes and induced cell death. In contrast, p38~
expression in the presence of MKK3 augmented hypertrophy and promoted cell
survival (Wang et al 1998). Thus p38a apparently promotes cell death whilst p38~
promotes cell hypertrophy.
Further evidence which links JNK and p38 MAPK to activation of apoptosis is the
finding that activation of the JNK and p38 MAPK pathways is associated with
activation of effector caspases, including caspase-3 (Chaudhary et al 1999).
Caspase-3 itself can also amplify the activation of the JNK pathway, as it is able to
cleave MEKK1 (Cardone et al 1997), a kinase upstream of JNK. Caspase-3
reinforces the inhibition of ERK by cleaving and inactivating Raf-1, an upstream
effector of the ERK signaling pathway (Windham et al 1998).
Strong evidence therefore exists for a connection between apoptosis, especially the
downstream effector caspase-3, and the MAPK family. The elements downstream of
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these MAP kinases leading to caspase activation and ultimately to apoptosis are still
not clearly defined.
1.3.5.2 Initiating a survival response
Incubation with SB 202190 alters the responses to endothelin-1, LlF or
phenylephrine (Nemoto et al 1998). Thus the p38 MAPKs have been proposed as
regulators of cardiac hypertrophy. Studies with SB 203580 have demonstrated its
lack of effect on the early changes in cell size stimulated by enothelin-1 or
phenylephrine, implying that the role of p38 MAPKs may actually be in the
maintenance of the hypertrophic response/survival over a long period of time (Clerk
et al 1998). There seems to be little doubt regarding the role of ERKs in the survival
response. Activation of ERK predominantly produces anti-apoptotic effects (Park et al
2000, Wang et al 1998). Despite the suggestion that JNK and p38 MAPKs mediate
cell death, ample evidence also supports their role in cell survival. TNF-a induced
activation of JNK and p38 MAPK enhances fibroblast survival (Roulston et al 1998),
JNK and p38 MAPKs protect during photodynamic therapy (Assefa et al 1999), and
one JNK isoform maintains survival following hypertonic shock (Wojtaszek et al
1998).
Evidence also supports these pro-survival signaling cascades. Anisomycin, an
activator of JNK and p38 MAPK, protected myocytes from ischaemie injury (Mackay
et al 1999) and phosphorylation of p38 MAPK correlated with preconditioning
protection (Weinbrenner et al 1997). Contradictory findings of anisomycin-initiated
cell death have however also been reported. Specific activation of p38 MAPKs by
Stellenbosch University http://scholar.sun.ac.za
43
overexpression of pathway components may also mediate a survival response in
cardiac myocytes (Zechner et al 1998). This is supported by p38p MAPK mediating
cell survival, sarcomeric organisation, and gene expression (Wang et al 1998).
The effects of different p38 MAPK and JNK isoforms are therefore likely to be
complex and dependent on the stimulus and cellular context. Duration and intensity
of the stress may ultimately determine the regulation of MAPKs and the final cellular
outcome. Also, the extent of p38 MAPK activation may dictate whether a cardiac
myocyte is committed to death or survival (Nagarkatti et al 1998).
1.3.6 Effect of preconditioning on apoptosis
Preconditioning has been extensively shown to reduce infarct size in different animal
species. Little is however known about the effect that IPC has on apoptosis. What is
known is that IPC does indeed protect the ischaemie heart against apoptosis
although the mechanism is as yet unknown.
A summary of publications on preconditioning and apoptosis is shown in table 1.2.
These provide evidence that cardioprotection elicited by preconditioning does protect
against apoptosis in the ischaemie heart. The relationship between these two
phenomena has been tested in various animal models, which include the rat, mouse,
dog, and cultured chick ventricular myocytes. A multi-cycle IPC protocol, as opposed
to a single cycle IPC protocol, followed by ischaemia and reperfusion and not just
ischaemia alone, appears to be the protocol of choice for many researchers
investigating how IPC affects apoptosis. Electrophoresis and the TUNEL assay, that
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Table 1.2: Literature review of preconditioning and apoptosis
Author Species Model Protocol Endpoint Technique
IPC (5 min LCA occlusion +5 min R) X 5 -DNA fragmentation -TUNEL assay
Piot et al (1997) Adult rat In vivo model -ELISA
20/30 min ischaemia +3h reperfusion -DNA laddering -electrophoresis
IPC (5min I + 10 min R) X 4 -DNA laddering -electrophoresis
Maulik et al (1998) Adult rat Perfused heart -DNA fragmentation -TUNEL assay
15 min ischaemia + 2h reperfusion -Left ventricular -Transducer
performance
IPC (3 min I + 3 min R) X 3 -DNA fragmentation -TUNEL assay
Okamura et al Adult rat Perfused heart
(1999) 30 min ischaemia + 6h reperfusion
IPC (5 min LCA occlusion +5 min R) X 5 -Internucleosomal -ELISA
Piot et al (1999) Adult rat Perfused heart DNA
20/30 min LCA occlusion +3h reperfusion -Caspase-1 -Western blotting
-Caspase-3
-PARP
IPC 10 min I + 15 min R -DNA fragmentation -TUNEL assay
Yadav et al (1999) Mouse Liver -electrophoresis
75 ischaemia -Caspase-3 -caspase-3 flourimetric-PARP assay
-PARP proteolysis
IPC 5 min I + 5 min R -DNA fragmentation -TUNEL assay
Wang et al (1999) Dog In vivo model
-electrophoresis
30 min ischaemia + 3h reperfusion
PC (1 min SI + 5 min reperfusion) X 3 -DNA fragmentation -TUNEL assay
Liu et al (2002) Chick Cultured cells
-DNA laddering -electrophoresis
embryos 10h simulated ischaemia + 12 h
reoxygenation
KEY: LeA
R
left coronary artery
reperfusion
I
SI
ischaemia
simulated ischaemia
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quantifies DNA laddering and DNA fragmentation respectively, also appear to be the
endpoint and technique mostly used.
Piot et al (1997) showed that hearts exposed to a multi-cycle IPC protocol of [ (5 min
ischaemia + 5 min reperfusion) x 5] before 30 of ischaemia followed by 3h of
reperfusion exhibited a reduction in DNA fragmentation and DNA laddering, used as
markers of apoptosis, compared to the Non-PC hearts. Maulik et al (1998) showed
similar results but in addition suggested that the lack of apoptotic cells and DNA
fragmentation resulted in better left ventricular performance in the preconditioned
myocardium compared to the non-preconditioned myocardium after reperfusion.
Recently, there has been a shift away from DNA damage to caspase activation as a
marker of apoptosis. In 1999, Piot et al showed that caspase-1, but more importantly
caspase-3 activation and PARP cleavage, widely regarded as key components in the
effector phase of apoptosis, were significantly reduced in IPC hearts compared to the
non-preconditioned hearts at the end of reperfusion using Western blotting. Yadav et
al (1999), using the mouse liver with a one-cycle IPC protocol but with no reperfusion
after ischaemia, showed similar significant decreases in both caspase-3 activation
and PARP cleavage after 75 min of ischaemia. They suggested that apoptosis is
decreased through downregulation of caspase-3. The role of caspase-3 as an
important marker and player in the apoptotic cascade has been mentioned
previously.
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The mechanism(s) by which ischaemic preconditioning prevents apoptosis remains
unknown. Gottlieb et al (1995) and Caceres-Cortes et al (1994) have demonstrated
that apoptosis could be delayed in neutrophils and in haematopoietic stem cells
respectively by preservation of intracellular pH homeostasis. On the basis of that
finding Gottlieb et al (1996) suggested that activation of the vacuolar proton ATPase
by PKC during preconditioning may attenuate intracellular acidification during
metabolic inhibition and thereby protect myocytes from apoptosis in vitro. Consistent
with these findings, Kida et al (1991), Schaefer et al (1995) and Wolfe et al (1993)
have demonstrated that IPC was accompanied by a reduction in intracellular acidosis
in rat hearts. In addition to increased proton export through vacuolar proton ATPase
by PKC activation, reduced proton production from anaerobic glycolysis may also
contribute to prevent myocyte apoptosis in rat hearts in vivo.
PKC and the MAPK stress kinases have also been implicated in the regulation of
apoptosis via IPC. Maulik et al (1996) using a multi-cycle IPC protocol [5 X (5 min
ischaemie + 10 min reperfusion )] before 30 min ischaemia and 30 min reperfusion
showed that IPC stimulated PKC, MAPK, and MAPKAP kinase 2 activities which
were inhibited by genistein, a tyrosine kinase inhibitor, when administered before the
IPC protocol. This group suggested that IPC may activate the tyrosine kinase-
phospholipase 0 signaling pathway in rat hearts, resulting in the activation of the
MAPK pathway. Studies by Han et al (2001) using oxidative stress with H202 as a
preconditioning stimulus in L (fibroblast) cells, showed that transient increases in p38
MAPK and JNK accompanied by drastically reduced caspase-3 activity was seen
after preconditioning. Furthermore SB 203580 abolished the protection provided by
PC. Their results point to a central role for p38 MAPK in mediating both the protective
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effects of oxidative preconditioning and the pro-apoptotic effects of prolonged
oxidative stress.
The data above provides strong evidence that preconditioning does protect the
ischaemie heart against apoptosis and the mechanism, although not yet fully
understood, seems to involve PKC and the p38 MAPK family. Further investigations
are needed to fully elucidate the mechanisms and implications of these mechanisms
in the ischaemically preconditioned hearts in reducing apoptosis.
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Aim of the study
The aim of the study was:
1. To establish a cell culture model of preconditioning using neonatal
cardiomyocytes. The reason for this is to enable one to elucidate the cardiac
specific signal transduction pathways more accurately, as a cardiomyocyte cell
culture would exclude the influence of non-cardiac cells. Furthermore, it
potentially offers a way of doing multiple experiments (i.e. looking at different
signal transduction components, and even different end-points) using a single
cell culture preparation, and thus enable rapid progression of the investigation.
2. To investigate whether IPC and PPC protect against ischaemia/reperfusion
damage as determined by measurements of both infarct size and apoptosis.
3. To determine the importance of the stress kinase, p38 MAPK, in the protective
effect of preconditioning against necrosis and apoptosis.
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Chapter 2
Materials and Methods
2.1 Neonatal cardiomyocytes in culture
2.1.1 Preparation of the cell culture
For the preparation of neonatal cardiomyocytes in culture, Wistar rats (2-4 days
old) were used. The neonatal rats were culled by intraperitoneal administration of
2.5% Intraval sodium (thiopentone sodium 2.5mg/rat) and upon death, immersed
in 70% alcohol. Neonatal cardiomyocytes were prepared by a modification of the
technique of Pinson (1990). Sterile conditions were employed throughout. The
chest was opened by a transverse cut with sterile scissors and the hearts
removed. The atria were cut off and discarded. The excised ventricles were
placed in a petri dish with a buffer containing (in mM): NaCI 120, KCI 5, 0-
glucose 6, Na2HP04.7H20 1, MgS04.7H20 0.3, HEPES 19, pH 7.4
The excised ventricles were transferred to a second petri dish containing the
above buffer, cut into smaller fragments with a pair of scissors and washed twice
with buffer. After washing, the buffer was replaced by the same buffer containing
0.3% collagenase and 0.06% pancreatine. The digestion process was performed
at 37°C in a shaking waterbath at a stirring rate of 50 strokes/min for 20 minutes.
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Remaining ventricular fragments were allowed to settle and the supernatant
transferred to a conical centrifuge tube. Newborn calf serum (NBCS) (20% v/v)
was added to the supernatant to stop the digestion process. The supernatant
was then centrifuged at 300 g for 5 minutes at room temperature. After
centrifuging, the supernatant was discarded and the cell pellet resuspended in 2
ml NBCS and kept at 37°C in the shaking water bath. Digestion of the ventricular
fragments was repeated until all the fragments were dissociated. The resulting
cell pellets were combined and centrifuged at 300 g for 5 minutes at room
temperature. To obtain a non-fibroblast containing myocyte preparation, use was
made of the isopyenic principle using Pereall with different gradients (Thandroyen
et al 1989). The final cell pellet was resuspended in 1.082g/ml Pereall on top of
which a 1.062g/ml and 1.050g/ml Pereall layer were loaded. The gradient was
centrifuged at 1000g for 25 minutes at 21°C. The cardiomyocytes were retrieved
from between the 1.082g/ml and 1.062g/ml Pereall layers, washed twice with the
buffer and then centrifuged at 300 g for 5 minutes at 21°C. The pellet was
diluted with Dulbecco's Modified Eagle's Medium (DMEM: with 10% Fetal Calf
Serum and 1% penicillin) to a final density of -800 000 cells/ml. Aliquots of 2ml
were seeded into 35mm petri dishes coated with 5 mq/cm" fibronectin. After
seeding, the cultures were incubated at 37°C in an atmosphere of 95% air/5%
CO2. After 3 days a confluent layer of beating cells was formed. The medium was
changed every 24 hours.
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2.1.2 Determination of cell viability in neonatal cardiomyocytes in culture
For the assessment of cell viability a modification of the 3-[4,5-Dimethyl-2-yl]-2,5-
diphenyl tetrazolium bromide (MTT) assay described by Gomez et al (1997) was
used. This assay is based upon the principle of reduction of MTT into blue
formazan pigments in viable cells. This reduction occurs only in the presence of
intact cell membrane and functional mitochondria, which makes it a marker of cell
viability as described in Chapter 1. At the end of experiments, the medium was
removed from the petri dishes and the cells washed twice with phosphate-
buffered saline (PBS). One ml of HCI-isopropanol-Triton (1% HCI in isopropanol;
0.1% Triton X 100; 50: 1) was added to each well and gently agitated for 5
minutes. This caused the cell membranes to lyse and liberate the formazan
pigments. The suspension was then centrifuged at 14 000 rpm for 2 minutes.
The optical density (00) was determined spectrophotometrically (Spectronic ® 20
Genesys ™- Spectronic Instruments) using glass cuvettes, at a wavelength of
540 nm.
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2.1.3 Preconditioning modalities: chemical hypoxia and ~-adrenergic
receptor stimulation
Two modalities were used to precondition neonatal cardiomyocytes:
(1) chemical hypoxia (5 min) or
(2) ~-adrenergic receptor stimulation by exposure to isoproterenol (10-7 M)
dissolved in Krebs Henseleit buffer (KHB) (5 min).
This chemical hypoxia solution was prepared by making a 1M KCN stock solution
i.e., 0.326g/5ml H20. From this stock solution, 1.15ml was mixed with 100 ~I of
10N HCI. From the resulting solution 250 ~I was added to 100ml KHB
immediately before use. Two ml of this solution was added per well to induce
chemical hypoxia.
2.1.4 Hypoxia modalities
Two methods of chemical hypoxia were employed:
(1) 5 mM KCN + 20 mM DOG in KHB for 5 min [Non-PC (DOG)] or
(2) 5 mM KCN in KHB for 45 min.
The first modality for chemical hypoxia used both KCN and DOG for 5 minutes
whereas the second modality only used KCN. This second modality was less
severe and thus a longer period of exposure i.e., 45 min was employed.
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2.1.5 Experimental protocols
The non-preconditioned cells were exposed to sustained chemical hypoxia only.
All PC cell cultures were preconditioned as described below before exposure to
simulated chemical hypoxia. The cells were washed twice with PBS between
each step of the protocol. DMEM refers to removal of the simulated chemical
hypoxia medium, washing with PBS and addition of DMEM with incubation in
95% CO2/5% O2.
Each preconditioning protocol was studied in triplicate and at least 6 different
neonatal cell preparations were used. The following protocols were attempted:
(I) Non-PC (DOG): oxygenated for 65 min + 5 min KCN + DOG + 10 min
DMEM
(II) 5 min KCN in KHB + 60 min DMEM + 5 min KCN + DOG in KHB + 10 min
DMEM
(III) Non-PC: oxygenated for 65 min + 45 min KCN + KHB + 10 min DMEM
(IV) 5 min KCN in KHB + 60 min DMEM + 45 min KCN in KHB + 10 min
OMEM
(V) 5 min isoproterenol in KHB + 60 min DMEM + 45 min KCN in KHB + 10
min DMEM
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Chemical Reoxygenation Sustained chemical Reoxygenation
hypoxia hypoxia
Time I I
(min) 0 5 65 70 80 110 120
(I) Non-P_C_(D_O_G_)--------i~::::l,__-
(II) PC
(III) Non-PC:..._ _
(IV) PC
(V) ~PC
KEY:
I = simulated chemical hypoxia with KCN
~ I = isoproterenol I
= simulated chemical hypoxia with KCN + DOG
Fig 2.1 Experimental protocols for the neonatal cardiomyocytes in culture.
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2.2 Isolated adult cardiomyocytes
2.2.1 Isolation of adult cardiomyocytes
For preparation of adult cardiomyocytes, a modification of the technique
described by Fischer et al (1991) was used.
2.2.1.1 Preparation of the buffers
Solution A: Calcium-free buffer containing (in mM): KCI 6, Na2HP04 1, NaH2 P04
0.2, MgS04 1.4, NaC1128, HEPES 10, glucose 5.5, pyruvate 2, pH 7.4
Solution B: Solution A containing 0.7% bovine serum albumin (BSA), fraction V,
fatty acid free, 1.1 mg collagenase/ml, and 15 mM 2,3-butanedione monoxime
(BOM).
Solution C: Equal volumes of solutions A and B were mixed and albumin (fraction
V, fatty acid free) was added to obtain a final concentration of 1.65%. CaCb was
added to obtain a final concentration of 200 ).lM. The temperature of the solution
was increased to 37°C in a shaking waterbath at 3rC, 180 strokes/min.
Solution 0: Solution A containing 2% BSA (fraction V, fatty acid free), and 1.25
mM CaCI2
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2.2.1.2 The perfusion technique
The perfusion system had two glass chambers containing solutions A and B
respectively. The buffers were oxygenated by gassing with 95% O2/5% C02 and
the temperature kept constant at 37°C. The excised heart was arrested in ice-
cold (4°C) Solution A and mounted onto the aortic canula. It was then
retrogradely perfused at a pressure of 100 cm H20 by the method of Langendorff
(Langendorff 1895) for 5 minutes with Solution A to rinse blood from the coronary
vessels. The perfusion was then switched to Solution B, and the first 8ml
coronary effluent was discarded. The remaining Solution B was recycled in the
system. After 20 minutes, 100 !JM of CaCI2 was added to Solution B and after 5
more minutes, another 100 !JM of CaCb was added. The completion of digestion
by collagenase usually occurred after ± 30 min, as indicated by a marked
increase in coronary flow rate. The heart was carefully detached and the atria
removed with a pair of scissors. The ventricles were carefully dissected with a
pair of tweezers and then transferred to oxygenated Solution C, agitated gently
and incubated in a shaking water bath for 15 minutes (37°C).
The cells were made calcium tolerant by increasing the calcium concentration of
the buffer step-wise to 1.25 mM over a period of 5 minutes. The cells were
filtered through a 200 x 200 urn mesh-filter and spun down at 100 rpm for 3
minutes at room temperature. The supernatant was removed and the cells
resuspended in Solution 0 by gentle tilting.
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The cells were allowed to settle for 5 minutes and the supernatant again
removed. The cells were transferred into a smaller volume of Solution 0 and
gently agitated for 1 hour at room temperature to stabilize. The cells were
washed twice with Solution 0 before experimentation. All isolates prepared in this
manner averaged 75-80% viability. A separate isolate was used for each
experiment.
2.2.2 Viability of adult cardiomyocytes
Cell viability was assessed by the trypan blue exclusion method and the MTT
assay.
2.2.2.1 The trypan blue exclusion method
This technique is based on the principle that an intact cell membrane excludes
trypan blue. Thus non-viable cells take up the trypan blue dye and stain blue,
whereas viable cells do not take up the dye, appear rod-shaped and have a
yellowish appearance.
2.2.2.1.1 Solutions
KCN solution: KCN (0.035% w/v)-solution 0 (1:1) was used to stop the cells from
beating.
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Trypan blue solution: 1% trypan blue in the above KeN solution containing 0.5%
glutaraldehyde was used as the counting medium.
2.2.2.1.2 Viability determination
For the assessment of viability at the beginning of the experiments a 12.5 1-11
aliquot was transferred from the initial pellet into 100 1-11 KeN-solution 0 (1: 1) and
resuspended gently, but thoroughly. For the assessment of viability at the end of
the experiments, 12.5 1-11 was taken from each experimental cell pellet and added
to 100 1-11 KeN solution as described above. The cells were allowed to settle for 3-
5 minutes and 25 1-11 from this suspension was added to 25 1-11 of the trypan blue
solution and mixed gently. A 12.5 1-11 aliquot from this homogenous solution was
then transferred to a counting chamber. Microphotographs were taken of the
non-beating myocytes (250-350 cells/sample), thereby allowing rapid recording
of data and minimizing unnecessary time-dependent absorption of the dye by
potentially viable cells. The number of viable cells was expressed as a
percentage of the total number of cells in the sample.
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2.2.2.2 The 3-[4,5- Dimethylthaizol-2-yl]-2,5-diphenyl-tetrazolium bromide
(MIT) assay
For the assessment of cell viability a modification of the MTT technique
described by Gomez et al (1997) was used. Upon completion of the experiment,
a volume containing 50 000 cells was transferred from each experimental group
into 35mm petri dishes. The volume per sample was made up to 500 IJl with
solution D. An equal volume of the MTT solution (1% MTT in Solution D) was
added and incubated at 37°C for 2 hours. The supernatant was removed and the
cells washed twice with phosphate-buffered saline (PBS). One ml of HCI in
isopropanol-Triton [1% HCI in isopropanol; 0.1% Triton X-100; (50:1)] was added
and gently agitated for 5 minutes. The suspension was centrifuged at 14 000 rpm
for 2 minutes. The optical density (00) was determined spectrophotometrically
(Spectronic ® 20 Genesys ™ - Spectronic Instruments) at a wavelength of 540
nm. For each experimental group the protein content was determined using the
Lowry method (Lowry et al 1951). Cell viability was expressed as OD/mg protein.
Viability assays of a particular cell preparation were always done in triplicate.
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2.2.3 Experimental protocols
Three experimental groups were studied viz., oxygenated controls, Non-PC
hypoxia, and preconditioned groups.
2.2.3.1 Oxygenated controls
Cells were incubated at 37°C under oxygenated conditions for the entire
duration of the experiment.
2.2.3.2 Non-PC hypoxia groups
For induction of hypoxia to adult cardiomyocytes, a modified technique of
Armstrong et al (1995) was used. The cells were spun down at 25.0 rpm for 2
minutes (so-called ischaemie pelletting). The excess supernatant was removed
until it equaled a third of the pellet size and a layer of mineral oil, just enough to
cover the surface i.e., -1 ml, was added to exclude air and induce hypoxia (care
was taken to prevent mixing of the cells and mineral oil). The cells were then
exposed to 2 hours of hypoxia at 37°C.
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2.2.3.3 Preconditioned groups
The cells were preconditioned by either a short episode of hypoxia or by p-
adrenergic receptor stimulation. The cells were subsequently exposed to 2 hours
of hypoxia as described above.
2.2.3.3.1 Ischaemic preconditioning (IPC)
As with the hypoxia groups, cells were spun down at 250 rpm for 2 minutes
(ischaemic pelletting), the supernatant removed until it was a third of the pellet
size, and a layer of mineral oil added (hypoxia). These cells were then incubated
at 37°C for 10 minutes. The cells were removed from under the oil layer and
resuspended in oxygenated solution 0 for 20 minutes, before being subjected to
2 hours of hypoxia as described in 2.2.3.2
2.2.3.3.2 p-adrenergic receptor stimulated preconditioning (PPC)
The cells were gently resuspended in Solution 0 containing 10-7 M isoproterenol
for 10 minutes at 37°C. The supernatant was removed and the cells washed
twice with oxygenated Solution 0 before allowing to settle for 20 minutes. After
this, cells were exposed to 2 hours of hypoxia as described above.
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Hypoxia Reoxygenation Sustained hypoxia
o
(I) Non-PC hypoxia
(II) IPC
(III) I3PC
KEY:
10 20 40 160
= hypoxia
= isoproterenol (10-7M)
Fig 2.2 Experimental protocols for the isolated adult cardiomyocytes.
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2.3 The isolated perfused heart
2.3.1 Perfusion technique of hearts used for determination of infarct size
For measurement of infarct size, hearts were perfused retrogradely at a constant
pressure of 100 em H20. A water filled latex balloon was inserted into the left
ventricle via the left atrium and the pressure recorded electronically and
displayed on a computer monitor. Data was stored and analyzed using computer
software developed by Mr. B. Genade. Left ventricular end-diastolic pressure
was set between 4-8 mm Hg as baseline. Normothermic zero-flow global
ischaemia was used to induce ischaemie preconditioning (3X5 min, alternated
with 5 min reperfusion) but the sustained ischaemia was regional and induced by
coronary artery ligation for 35 min followed by 30 min reperfusion. Reperfusion
was initiated by loosening of the ligation. At the end of the experiment, the silk
suture around the coronary artery was securely tied and -1 ml of a 0.5% Evans
Blue suspension slowly injected via the aorta cannula. The heart was then frozen
overnight before being cut into 2 mm thick slices. After defrosting, the slices were
stained with 1% w/v triphenyltetrazolium chloride in phosphate buffer (pH 7.4) at
37 oe for 15 minutes. Slices were then fixed in 10% v/v formaldehyde solution to
enhance the contrast between stained viable tissue and unstained necrotic
tissue.
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The area of the left ventricle at risk and the area of infarcted tissue in the risk
zone were determined using computerized planimetry (Summa Sketch II; Summa
Graphics). The volume of infarcted tissue (I) and the risk zone (R) was then
calculated by multiplying each area with the slice thickness and calculating the
sum of the products. The infarct size was expressed as the percentage of the risk
zone (I/R %).
2.3.2 Perfusion technique of hearts used for biochemical determinations
The isolated working rat heart as described by Edoute et al (1988) was used as
an experimental model. The hearts were rapidly excised and arrested in ice cold
(4°C) Krebs-Henseleit bicarbonate buffer containing (mM): NaCI 119, NaHC03
25, KCI 4.75, KH2P04 1.2, MgS04 0.6, NaS04 0.6, CaCI2 1.25, Glucose 10, pH
7.4
After removal, the hearts were perfused by the Langendorff technique
(Langendorff 1895) in a retrograde, non-recirculating manner with Krebs-
Henseleit buffer oxygenated with 95% O2/5% CO2 at 37°C. The left atrium was
cannulated to allow atrial perfusion according to Neely et al (1984) as modified
by Opie at al (1971).
Normothermic zero-flow global ischaemia was used to induce ischaemie
preconditioning. The global ischaemia, for 25 min, was achieved by simultaneous
clamping of both the aortic and left atrial cannulae. Temperature was carefully
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controlled and maintained at 36.5 DCduring sustained ischaemia by continuously
monitoring using a temperature probe inserted into the pulmonary artery. Hearts
were subsequently reperfused for 30 min (10 min retrogradely, 20 min working
heart) by unclamping the tube to the aortic cannula. Hearts were freeze-clamped
at the end of reperfusion for subsequent analyses.
2.3.3 Experimental protocols using infarct size as endpoint
2.3.3.1 Controls
Control hearts were perfused for 30 or 60 min under oxygenated conditions
before freeze-clamping of tissue.
2.3.3.2 Non-preconditioned hearts (Non-PC)
Hearts were stabilized for a period of 60 min (15 min retrograde, 15 min working
heart, 30 min retrograde), followed by 35 min regional ischaemia and 30 min
reperfusion (10 min retrograde, 20 min working heart).
2.3.3.3 Ischaemie preconditioned hearts (IPC)
Hearts were stabilized for a period of 30 min (15 min retrograde, 15 min working
heart) and then preconditioned by 3 x 5 min global ischaemia, alternated with 5
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min reperfusion. Hearts were subsequently subjected to 35 min regional
ischaemia and 30 min reperfusion as described above.
2.3.3.4 l3-adrenergic receptor stimulated preconditioned hearts (BPC)
Hearts were stabilized for 50 minutes (15 min retrograde, 15 min working, 20 min
retrograde) after which 10-7M of isoproterenol was introduced for 5 minutes, and
then subsequently washed out for 5 minutes, before induction of sustained
regional ischaemia and reperfusion as described above.
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TIME I I I I I I I I I I I
(min) o 15 30 35 40 45 50 55 60 95 105 125
I Working heart . - JI Retrograde I
(II) Non-PC
I Retrograde I "..,.,.,.,.,.,...,.,...I Retrograde III Working heart I
(III) IPC
[R~~;~~~cleI I W~;k-i~~heart] "..,.,.,.,...,.,. ......I Retr~~;~d~J II Working heart I
(IV) ~PC
[ R~t;ograde I I Working heart I IL I Retrograde III Working heart I
KEY: I = global ischaemia I ~ I = regional iscl1~~r1"li~--1 [:-T;oproterenol I
Fig 2.3 Experimental protocols for the effect of preconditioning on infarct size in isolated perfused hearts.
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2.3.3.5 SB203580 treated hearts
SB 203580, a blocker of p38 MAPK, was used at a concentration of 2 I-LMin a
number of studies. The following protocols preceded 35 min regional ischaemia
and 30 min reperfusion:
(1) hearts were stabilized for 50 min (15 min retrograde, 15 min working, 20
min retrograde), followed by 10 min administration of SB 203580,
(2) hearts were perfused retrogradely for 15 min, followed by 10 min in the
working mode. SB 203580 was administered for 5 min before and after the
first PC episode and also after the second PC episode. After the third PC
episode, hearts were perfused for 10 min to ensure washout of the drug.
2.3.3.6 Anisomycin stimulated preconditioned hearts
Anisomycin at a concentration of 5 I-LMwas used. The following protocols
preceded 35 min regional ischaemia and 30 min reperfusion (see above) of the
isolated hearts:
(1) 15 min retrograde, 15 min working, 20 min retrograde, followed by 10 min
anisomycin
(2) 15 min retrograde, 15 min working, 10 min retrograde, followed by 10 min
anisomycin; 10 min reperfusion.
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TIME
(min) o 15 25 30 35 40 45 50 55 60 65 95 100 105 110 125 130
I Retrograde II l Working heart -J I Retrograde I r. . . . . . . It>: ........ ,.,. 'uno:.. IR~;r~~de III Working heart I
(I) SB (1)
I Retrograde II I Working heart I
"' 'L 'L 'L 'L 'L 'L 'L 'L 'L" I Retrograde II [ w~~ki~~rt]
(II) SB (2)
KEY: I = global ischaemia I ~ I = regional ischaemia I I:~::J I = SB 203580 I
Fig 2.4 Experimental protocols for the effect of p38 MAPK inhibition with SB 203580 (1) before ischaemia/reperfusion and
(2) during the IPe protocol on infarct size in isolated perfused hearts.
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TIME I I I I I I I I
(min) o 15 30 40 50 60 95 105 125
(III) Anisomycin (1)
I Retrograde II [working heart I I Retrograde I I Retrograde lil Working hea~ . --I
(IV) Anisomycin (2)
I Retrograde III Working heart II r- Ret~~~~;d~J il .. " " " " " " " " ". I Retr~g;~d~~ II Working h~~~ ml
KEY: ~ I= regional ischaemia I D I= anisomycin I
Fig 2.5 Experimental protocols for the effect of p38 MAPK activation with anisomycin (1) before ischaemia/reperfusion and
(2) as a trigger on infarct size in isolated perfused hearts.
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2.3.4 Experimental protocols using markers of p38 MAPK activation and
apoptosis as endpoint
The same protocols as described in 2.3.3 were used. The only difference was
that hearts were subjected to 25 min global ischaemia in contrast to 35 min
regional ischaemia (Fig 2.6, Fig 2.7 and Fig 2.8).
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I _j I_I I I I I I I
(min) o
I Retrograde I
(II) Non-PC
1- Il li-TT-1 1-I
15 30 35 40 45 50 55 60 85 95 115
[WOfki~gh~~~-1 I RetrOgrade] rRetrOgrad~] II Working heart - -I
(III) IPC
I Retrograde I
I Retrograde n 1
I Working heart 1 ~tro~~~d~-J II Workin~rt I
~~rograde 111- Working heart 1[WOiling heart I
(IV) PPC
KEY: I = global ischaemia I [~-i~~Prcleren~1I
Fig 2.6 Experimental protocols for the effect of preconditioning on p38 MAPK activation, caspase-3 activation and PARP cleavage in
isolated perfused hearts.
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TIME
I I I I I I I I I I I I I I I I
(min) o 15 25 30 35 40 45 50 55 60 65 85 90 95100 115 120
I Retrograde II r Working heart I 1- Retrograde I I Retrograde III Working heart I
(I) SB (1)
I Retrograde II I Working heart I I Retrograde II [.Working heart I
(II) SB (2)
KEY: I= global ischaemia I I~~~~jI = SB 203580 I
Fig 2.7 Experimental protocols for the effect of p38 MAPK inhibition with SB 203580 (1) before ischaemia/reperfusion and
(2) during the IPC protocol on p38 MAPK activation, caspase-3 activation and PARP cleavage in isolated perfused hearts.
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TIME I I I I I I I I
(min) o 15 30 40 50 60 85 95 115
(III) Anisomycin (1)
I Retrograde III-working heart I rRetrOgrade I I Retrograde II ! Working heart I
(IV) Anisomycin (2)
! Retrograde III Working heart II [Retrograde I .. [RetrOgrade II ! Working heart I
KEY: I = global ischaemia I D I= anisomycin I
Fig 2.8 Experimental protocols for the effect of p38 MAPK activation with anisomycin (1) before ischaemia/reperfusion and
(2) as a trigger on p38 MAPK activation, caspase-3 activation and PARP cleavage in isolated perfused hearts.
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2.3.5 Experimental protocols for the collection of tissue samples
Hearts were freeze-clamped with precooled Wollenberger tongs at different times
of the perfusion protocol and plunged into and stored in liquid nitrogen. The
freeze-clamped tissue was homogenized and treated with a lysis buffer
containing (in mM): Tris 20, P-nitrophenylphosphate 20, EGTA 1, NaF 50,
Sodium orthovanadate 0.1, Phenyl methyl sulphonyl flouride (PMSF) 1,
Dithiotreitol (OTT) 1, Aprotinin 10 !-lg/ml, leupeptin 10 !-lg/ml. The tissue Iysates
were diluted in laemmli sample buffer, boiled for 5 minutes and the appropriate
amount of protein was separated by electrophoresis on the appropriate
percentage polyacrylamide gel, using the Bio-RAD Mini-PROTEAN " System.
The lysate protein content was determined using the Bradford technique.
The separated proteins were transferred to a PVDF membrane (Irnrnobilon" P,
Millipore). These membranes were stained with Ponceau Red for visualization of
proteins. Non-specific binding sites on the membranes were blocked with 5% fat-
free milk in Tris-buffered saline [fris 4.84% w/v and NaCI 16% w/v in deionised
water; pH 7.6)- 0.1% Tween 20 (TBST)]. The activated enzyme was visualized
with the appropriate primary antibody. Membranes were subsequently washed
with large volumes of TBST (3x1 min and then 2x5 min) and the immobilized
antibody conjugated with a diluted horseradish peroxidase-labelled secondary
antibody (Amersham LIFE SCIENCE). After thorough washing with TBST,
membranes were covered with ECl detection reagents and exposed to an
autoradiography film (Hyperfilm ECl, RPN 2103) to detect light emission through
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a non-radioactive method (ECl Western blotting). Films were densitometrically
analyzed (UN-SCAN-IT, Silkscience).
2.3.5.1 p38 mitogen activated protein kinases (p38 MAPK)
10 fl9 of protein was separated by electrophoresis on a 12% polyacrylamide gel
and the primary antibody used was dual phosphorylated p38 MAPK
(Thr180/tyr182) (Cell Signaling - Massachusetts, USA).
2.3.5.2 Caspase-3
The following procedure was done according to the technique of Scháqqer and
Von Jagow (1987). 50 fl9 protein was separated by electrophoresis on a 4% T,
3% C stacking and a 16.5% T, 3% C separating gel. T denotes the total
percentage concentration of both monomers (acrylamide and bisacrylamide). C
denotes the percentage concentration of the crosslinker relative to the total
concentration. The anode buffer used contained 0.2M Tris at a pH of 8.9 and the
cathode buffer contained 0.1M Tris; 0.1M Tricine, and 0.1% sodium dodecyl
sulphate (SOS) at a pH of 8.25. The primary antibody used was an anti-cleaved
Caspase-3 (Asp 175) (Cell Signaling - Massachusetts, USA).
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2.3.5.3 Poly ADP ribose polymerase (PARP)
50 !lg of protein was separated by electrophoresis on a 12% polyacrylamide gel
and the primary antibody used was an Anti-PARP p85 fragment (Promega
Corporation - Wisconsin, USA).
2.4 Chemicals
Bovine serum albumin, bovine serum albumin fraction V, and collagenase for the
neonatal cells in culture were obtained from Roche (Basil, Switzerland).
Collagenase for the preparation of isolated adult cardiomyocytes was obtained
from Worthington Biochemical Corporation (New Jersey, USA). Isoproterenol
was obtained from Adcock Ingram (Gauteng, RSA) and SB 203580 from
Calbiochem (California, USA). All other analytical grade chemicals were
purchased from Sigma (St. Louis, USA) or Merck (Darmstadt, Germany).
2.5 Statistical Analysis
Results are expressed as mean ± SEM (standard error of the mean). P-values
were determined by ANOVA and subjected to a TUKEY post-hoc analysis.
Values of p < 0.05 were regarded as statistically significant. In certain series of
experiments, groups were compared using the unpaired Student's T-test
(explained later).
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Chapter 3
Results
3.1 Neonatal myocytes
3.1.1 Optimization of MTT assay for cultured neonatal cardiomyocytes
The first aim was to optimize conditions for the MTT assay in order to evaluate
viability of neonatal cardiomyocytes. The optimum concentration of MTT to use in
cultured cardiomyocytes had to be established. Three final concentrations of
MTT solution i.e., 0.05%, 0.1% and 0.25% were tested in the same cell
population size (650 000 - 800 000 cells/ml). After 2 hours of incubation at 37 oe
with the MTT solution, there was no significant difference in the optical density
(00) readings at 540 nm between the groups exposed to 0.05% and 0.1% of
MTT solution respectively (Fig 3.1). However, 0.25 % of MTT solution produced a
significant increase in the 00 readings of the particular cell population when
compared to both the 0.05% (p < 0.01) and 0.1 % (p < 0.01) of MTT solution
respectively (p < 0.05 for overall comparison). Further increases in MTT
concentration did not increase the 00 readings (results not shown). Therefore
0.25% of a MTT solution added to the wells was used throughout subsequent
experiments on neonatal cardiomyocytes in which viability was assessed.
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Fig 3.1 Optimization of MTT concentration for neonatal
cardiomyocytes in culture
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For each series, 2 different neonatal preparations were studied.
Each condition was studied in duplicate.
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3.1.2 Optimization of the preconditioning protocol for neonatal
cardiomyocytes in culture
Three protocols were tested for their ability to elicit preconditioning in the cultured
neonatal cardiomyocytes and were compared to the non-preconditioned (Non-
PC) cells, which were exposed to chemical hypoxia only (see "Materials and
Methods" 2.1.5). The MTT assay was used throughout the experiments as an
indicator of cell viability. All experiments were performed at 37°C.
The first protocol tested was:
(i) 5 minutes exposure to 5 mM KCN as a preconditioning stimulus or
"trigger" followed by 60 minutes of reoxygenation in DMEM. This was
followed by 5 minutes exposure to a combination of KCN and
deoxyglucose (DOG), used as the chemical simulated ischaemia ("test
ischaemia"), followed by 10 minutes of reoxygenation in DMEM.
This protocol was not successful in preconditioning the cells, as the MTT assay
showed no significant difference in viability at the end of 5 min chemical
ischaemia (using KCN + DOG) and 10 min of reoxygenation between the PC and
Non-PC groups (Fig 3.2).
Stellenbosch University http://scholar.sun.ac.za
Fig 3.2 Effect of preconditioning on neonatal cell viability.
Preconditioning protocol: 5 min KCN, 60 min reox.,
"Test ischaemia" 5 min KCN + DOG, 10 min reox.
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For each series, 4 different neonatal preparations were studied.
Each condition was studied in triplicate or quadruplicate.
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Exposure to simulated ischaemia of longer duration, but without DOG was
decided upon:
(ii) 5 minutes exposure to 5 mM KCN as a preconditioning stimulus followed
by 60 minutes of reoxygenation in DMEM was used as before. This was
followed by 45 minutes exposure to KCN only, as the chemical simulated
ischaemia ("test ischaemia"), followed by 10 minutes of reoxygenation in
DMEM.
In a limited number of experiments (n = 10 different neonatal preparations), cells
that were preconditioned before 45 min of simulated ischaemia showed a
significant increase in viability when compared to cells that were only exposed to
45 min of simulated ischaemia and 10 min reoxygenation i.e., Non-PC groups
(Fig 3.3). This PC protocol however, failed to consistently precondition the
neonatal cells from one cell preparation to the next. In an almost equal number of
experiments (n = 11 different neonatal preparations), the viability of the PC
groups was not statistically different from that of the Non-PC groups at the end of
reoxygenation (Fig 3.4). The combined results of all these experiments (n=21)
are shown in Fig 3.5A and as a scattergram in Fig 3.58.
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Fig 3.3 Effect of preconditioning on neonatal cell viability.
Preconditioning protocol: 5 min KCN, 60 min reox.,
"Test ischaemia" 45 min KCN, 10 min reox.
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For each series, 10 different neonatal cell preparations were studied.
Each condition was studied in triplicate.
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Effect of preconditioning on neonatal cell viability.
Preconditioning protocol: 5 min KCN, 60 min reox.,
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For each series, 11 different neonatal cell populations were studied.
Each condition was studied in triplicate.
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Fig 3.5A Effect of preconditioning on neonatal cell vaibility
Preconditioning protocol: 5 min KCN, 60 min reox.,
"Test ischaemia" 45 min KCN, 10 min reox.
E 0.20c
0..q
LO..... 0.15ca
IJ)
0)
c
"C 0.10ca
Q)....
Cl
0
0.05
For each series, 21 different neonatal cell populations were studied.
Each condition was studied in triplicate.
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Fig 3.58 Effect of preconditioning on neonatal cell viability.
Preconditioning protocol: 5 min KCN, 60 min reox.,
"Test ischaemia" 45 min KCN, 10 min reox.
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All attempts to clarify this inability of the neonatal cardiomyocytes in culture to
consistently precondition were unsuccessful. The following factors were
considered:
(i) Human error: more stringent attention to techniques employed in the
preparation of the cultures such as aseptic technique; quantities,
temperature and pH of buffers/solutions used in the preparation of the
cultures was adhered to in order to prepare cultures that would be as
identical as possible in terms of appearance and confluency on day 3. Day
3 was chosen as it represented the best degree of confluency in cultures
that were previously successfully preconditioned.
(ii) Age of the neonates: the age of neonates used to prepare the cultures
were varied. Neonates ranging from 1 to 4 day were used. Cultures were
prepared using only one particular age of neonate viz. 3 day old neonates.
(iii) The growth medium was changed every 24 hours as opposed to every 48
hours to remove the cells that did not adhere to the fibronectin. These
cells could deprive the adhering cells of nutrients and were seen as a
possible factor that could affect confluency later on.
(iv) Optimal confluency was reached from day 3 onwards, and
experimentation was therefore done with these preparations. Neonatal cell
cultures older than 3 days were also used to assess the influence of cell
maturity on the results. However, no consistent preconditioning was
observed with these older cultures either.
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Since ischaemic preconditioning of the neonatal cells in culture was not
producing the desired results it was decided to investigate the possibility that
pharmacological preconditioning, for example p-adrenergic receptor stimulated
preconditioning in particular, would provide us with the means to consistently
precondition the neonatal cells in culture.
Thus the third protocol was:
(iii) Exposure of the cells to 10 minutes of 10-7 M isoproterenol, which was
subsequently washed out with PBS. This was followed by 60 minutes
reoxygenation in OMEM and 45 minutes in KCN (used as chemical
simulated ischaemia) and finally 10 minutes reoxygenation in OMEM.
Unfortunately this PC protocol too caused no significant difference in cell viability
after 45 min of simulated ischaemia and 10 min of reperfusion when compared to
the Non-PC groups (Fig 3.6).
In order to assess the effects of ischaemia/hypoxia on myocardial necrosis and
apoptosis, a reliable model of preconditioning was an absolute prerequisite. In
view of the inexplicable variations in the outcome of the experiments performed,
it was decided to switch to another model viz., the adult cardiomyocyte. It has
been shown in our laboratory to precondition successfully (H. Strijdom,
unpublished observations).
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Fig 3.6 Effect of preconditioning on neonatal cell viability.
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Two different neonatal cell preparations were used.
These were studied in triplicate.
Iso = isoproterenol (10-7 M)
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3.2 Preconditioning of isolated adult cardiomyocytes
Isolated adult cardiomyocytes used for the experiments were of optimal quality:
Viability (expressed as the percentage trypan blue excluding cells) averaged
between 70-80 % at time zero. Isolates with less than 70 % trypan blue exclusion
were discarded. The difference between control cells, preconditioned cells (10
min hypoxia followed by 20 min reoxygenation) and Non-PC cells exposed to 2h
of hypoxia was significant (p < 0.0001). Cells exposed to 2 hours of hypoxia only
i.e., Non-PC showed a significant reduction (15.6 ± 1.9%) in viability when
compared to cells incubated under oxygenated conditions (71.6 ± 3.0%) (p <
0.001). Preconditioned cells had a significantly higher viability (37.2 ± 6.0%) after
2h of hypoxia compared to the Non-PC groups (15.6 ± 1.9%) (p < 0.01) (Fig 3.7).
The MTT assay also showed similar significant increases in viability (OD/mg
protein) when comparing the Non-PC groups to the controls and PC groups
respectively (results not shown).
Although the isolated adult cardiomyocytes proved to precondition both
successfully and consistently, the cell yield from one heart was insufficient to
perform simultaneous evaluations of p38 MAPK, caspase-3 activation and PARP
cleavage as well as cell viability. It was therefore decided to use the isolated
perfused heart in all further experiments.
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Fig 3.7 Effects of preconditioning on viability of isolated adult
cardiomyocytes (trypan blue exclusion method)
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Five isolated adult cardiomyocyte preparations were used.
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3.3 The isolated perfused heart
This model yields enough material for the simultaneous assessment of necrosis,
apoptosis and p38 MAPK activation. This model also allows for pharmacological
manipulation of p38 MAPK activation during both the ischaemie preconditioning
protocol and during sustained ischaemia, and to evaluate the effects thereof on
necrosis and apoptosis.
3.3.1 Effects of ischaemie and pharmacological preconditioning on
necrosis, p38 MAPK activation and apoptosis
3.3.1.1 Infarct size (% of area at risk) (Fig 3.8)
The infarct size of the Non-PC and two PC groups differed significantly (Anova:
p < 0.001). Infarct sizes of hearts that were ischaemically preconditioned by 3 x 5
min global ischaemia (12.2 ± 1.4%) and pharmacological preconditioning WPC)
with a 1 x 5 min cycle of isoproterenol (10-7M) (15.2 ± 2.6%) were significantly
less than ischaemie hearts that were hot preconditioned (29.6 ± 2.9%) (p < 0.001
for both comparisons).
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Fig 3.8 Effects of preconditioning on infarct size of
perfused hearts (TTC staining)
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3.3.1.2 p38 MAPK (Fig 3.9)
p38 MAPK activation differed significantly between the groups (Anova:
p < 0.0001). Exposure of the heart to 25 min global ischaemia followed by 30 min
reperfusion (Non-PC hearts) caused a significant increase in p38 MAPK
activation (223 800 ± 7812 pixels) when compared to the control hearts (43070 ±
4535 pixels) (p < 0.001). p38 MAPK activation of IPC and PPC hearts were
similar to controls and significantly lower than that of the Non-PC hearts
(p < 0.001 for both comparisons)
3.3.1.3 Caspase-3 (Fig 3.10)
Caspase-3 activation differed significantly between the different groups (Anova:
p < 0.05). Hearts that were not preconditioned showed a marked increase in
caspase-3 activation (136200 ± 25310 pixels) when compared to the control
hearts (60590 ± 18090 pixels) (p < 0.05) (Fig 3.10). Preconditioned hearts (IPC
and PPC) showed statistically significant lower caspase-3 activation
(69750 ± 17460 pixels and 43100 ± 6168 pixels respectively) compared to the
Non PC hearts (p < 0.05 for both comparisons).
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Fig 3.9 Effects of of preconditioning on p38 MAPK
activation of perfused hearts at the end of reperfusion
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Fig 3.10 Effects of preconditioning on caspase-3 activation
of perfused hearts at the end of reperfusion
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3.3.1.4 PARP (Fig 3.11)
PARP cleavage as measured by Western blotting differed significantly between
the different groups (Anova: p < 0.05). Exposure of the heart to 25 min global
ischaemia followed by 30 min reperfusion i.e., Non-PC hearts, caused a marked
increase in PARP activation, and hence apoptosis, at the end of reperfusion
(383100 ± 55330 pixels) when compared to the control hearts (262500 ± 26540
pixels) (p < 0.05). Hearts preconditioned with both ischaemia and isoproterenol
showed a significant decrease (p< 0.05 for both comparisons) in PARP activation
(217500 ± 42550 pixels and 170300 ± 39900 pixels respectively) when compared
to the Non-PC hearts (Fig 3.11).
These results indicate that apoptosis was decreased by IPC and ~PC and was
accompanied by reduced activation of p38 MAP kinase.
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Fig 3.11 Effects of preconditioning on PARP cleavage
of perfused hearts at the end of reperfusion
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3.3.2 Effects of manipulation of p38 MAPK by 58203580 on necrosis, p38
MAPK activation and apoptosis
The next question that was addressed was the role of p38 MAP kinase in
mediating the protective effect of preconditioning against ischaemia/reperfusion
induced apoptosis.
Work performed in our laboratory (Marais et al 2001 a) has shown that ischaemia
of 5 min duration activated p38 MAPK. By appropriate use of the p38 MAPK
blocker SB 203580, the role of p38 MAPK as a trigger and/or mediator of
ischaemie preconditioning was evaluated. Administration of SB 203580
immediately before onset of sustained ischaemia and without washout allowed
evaluation of its role as mediator of protection (SB 2035080 (1)). Administration
of the drug, before and during the IPC protocol, but followed by washout before
sustained ischaemia, allowed evaluation of its role as trigger (SB 203580 (2)).
3.3.2.1 Infarct size (% area at risk) (Fig 3.12)
Infarct size differed significantly between the different groups (Anova:
p < 0.0001). Hearts treated with SB 203580 10 min before ischaemia without
washout (12.6 ± 1.9%) and hearts treated with SB 203580 during the 3 x 5 min
preconditioning protocol showed a significant reduction in infarct size at the end
of reperfusion (14.1 ± 2.9%) compared to the Non-PC hearts (29.6 ± 2.9%)
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Fig 3.12 Effects of SB 203580 on infarct size of
perfused hearts (TTC staining)
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(p < 0.001). Infarct size of the two SB 203580 treated groups were similarly
reduced.
3.3.2.2 p38 MAPK (Fig 3.13)
p38 MAPK activation of all the different groups differed significantly (Anova:
p < 0.0001). p38 MAPK activation of hearts perfused with SB 203580 10 min
(without washout) before ischaemia and bracketing of the IPC protocol (i.e.,
administered during preconditioning and washed out before sustained ischaemia)
(48710 ± 4192 and 70550 ± 8011 respectively) was significantly less than that of
the Non-PC hearts (223800 ± 7812) (p < 0.001 for both comparisons).
3.3.2.3 Caspase-3 (Fig 3.14)
Caspase-3 activation of the different groups differed significantly (Anova:
p < 0.05). Inhibition of p38 MAPK with SB 203580 10 min before sustained
ischaemia reduced caspase-3 activation (54860 ± 5517 pixels) when compared
to the Non-PC groups (136200 ± 25310) (p < 0.05). Hearts treated with SB
203580 during the 3 x 5 min IPC protocol, showed no significant difference in
caspase-3 activation (98930 ± 12060 pixels) when compared to the Non-PC
hearts.
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Fig 3.13 Effects of SB 203580 on p38 MAPK activation
of perfused hearts at the end of reperfusion
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Fig 3.14 Effects of SB 203580 on caspase-3 activation
of perfused hearts at the end of reperfusion
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3.3.2.4 PARP (Fig 3.15)
PARP cleavage differed significantly between the different groups (Anova:
p < 0.05). Neither the Tukey nor the Newmans- Keuls post hoc tests could
localise differences. This was probably due to large standard errors, which were
attributed to inter-series differences. Intergroup differences were therefore
investigated by an unpaired Students t-test. Hearts that were not preconditioned
showed a marked increase in PARP cleavage (383100 ± 55330 pixels) at the
end of reperfusion when compared to the control hearts (202500 ± 26540 pixels)
(p < 0.05). SB 203580, when administered 10 min before sustained ischaemia
showed a statistically significant lowering of PARP cleavage (211780 ± 45470
pixels) when compared to the Non-PC groups (p < 0.05) (Fig 3.15). When SB
203580 was administered during the 3 x 5 min IPC protocol, PARP cleavage
(259900 ± 29840 pixels) was not significantly less than that of the Non-PC hearts
(p = 0.07) (Fig 3.15). A representative blot of one experiment is shown.
Stellenbosch University http://scholar.sun.ac.za
Fig 3.15 Effects of SB 203580 on PARP cleavage of
perfused hearts at the end of reperfusion
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3.3.3 Effects of manipulation of p38 MAPK by anisomycin on necrosis,
p38 MAPK activation and apoptosis
In the next series of experiments it was attempted to increase p38 MAPK
activation on order to study its role in the protective effect of preconditioning on
apoptosis and infarct size.
To determine whether activation of p38 MAPK by anisomycin can act as a
mediator or trigger of preconditioning, the drug was administered either 10 min
before sustained ischaemia (anisomycin (1)) or 10 min followed by washout
(anisomycin (2)).
3.3.3.1 Infarct size (% area at risk) (Fig 3.16)
The infarct size of Non-PC and anisomycin-treated hearts differed significantly
(Anova: p < 0.0001). Administration of anisomycin for 10 min before sustained
ischaemia resulted in an infarct size (16.6 ± 2.4%) that was significantly lower
than the non-preconditioned hearts (29.6 ± 2.9%) (p < 0.01). Administration of
anisomycin for 10 min and washed out for 10 min before also caused a
significant reduction in infarct size (14.9 ± 2.2%) which was significantly lower
than that of the Non-PC hearts (p < 0.001) (Fig 3.16).
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Fig 3.16 Effects of anisomycin on infarct size
of perfused hearts (TTC staining)
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3.3.3.2 p38 MAPK (Fig 3.17)
p38 MAPK activation of all the different groups differed significantly (Anova:
p < 0.0001). Administration of anisomycin either 10 min before sustained
ischaemia, or when anisomycin is administered for 10 min and then washed out
for 10 min before sustained ischaemia both resulted in p38 MAPK activation at
the end of reperfusion that was significantly higher than that of the control
(p < 0.001 for all comparisons). p38 MAPK activation of both anisomycin groups
was however significantly less than that of Non-PC hearts (p < 0.001 for all
comparisons ).
3.3.3.3 Caspase-3 (Fig 3.18)
Caspase-3 activation differed significantly between the different groups (Anova:
p < 0.05). Caspase-3 activation was significantly less when anisomycin was
administered for 10 min before sustained ischaemia, and when administered for
10 min and then washed out before sustained ischaemia when compared to the
values obtained in the Non-PC groups (136200 ± 25310 pixels) (p < 0.05 for both
comparisons ).
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Fig 3.17 Effects of anisomycin on p38 MAPK activation of
perfused hearts at the end of reperfusion
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Fig 3.18 Effects of anisomycin on caspase-3 activation
of perfused hearts at the end of reperfusion
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3.3.3.4 PARP (Fig 3.19)
PARP activation differed significantly between the different groups (Anova:
p < 0.05). Anisomycin when administered for 10 min before sustained ischaemia
or when administered for 10 min and then washed for 10 minutes before
sustained ischaemia, caused no significant difference in PARP activation
(181000 ± 51540 pixels and 169900 ± 8298 pixels respectively) when compared
to the control hearts.
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Fig 3.19 Effects of anisomycin on PARP cleavage
of perfused hearts at the end of reperfusion
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Chapter 4
Discussion
Introduction
In this thesis we investigated the possible role of activation of the stress kinase, p38
MAPK, in the protective effect of preconditioning against ischaemia/reperfusion injury.
The main findings of the work are as follows:
1. A method for determination of cell viability was developed and established in the
laboratory- the MTT staining method. The method is easy to use, and will be useful
in future.
2. The attempt to develop a cell culture model of preconditioning using neonatal
cardiomyocytes proved unsuccessful, and although a model of isolated adult
cardiomyocytes was potentially useful, it was not utilized as the yield of materialwas
too low to perform multiple simultaneous biochemical determinations.
3. The isolated perfused rat heart was subsequently used for experimental work, with
infarct size as endpoint. This model demonstrated the phenomenon of
preconditioning convincingly and reliably using two different triggers of
preconditioning - ischaemia and pharmacological preconditioning with isoproterenol.
Preconditioning with both ischaemia and isoproterenol protected against
ischaemia/reperfusion damage as was demonstrated by both a reduction in infarct
size and a reduction in apoptosis. This has not been shown before for isoproterenol
mediated preconditioning, and is thus a unique finding.
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4. Investigations into the role of activation of p38 MAPK in the protective effect of
preconditioning against ischaemia/reperfusion damage showed that inhibition of p38
MAPK activation during sustained ischaemia mediated protection against both
infarction and apoptosis. Furthermore, activation of p38 MAPK did not act as a
trigger for protection against infarction. Inhibition of p38 MAPK during the triggering
phase was however associated with a minor, but significant increase in apoptosis in
the reperfusion phase, which suggest that activation of p38 MAPK prior to sustained
ischaemia was important for protection against apoptosis.
5. The importance of activation of p38 MAPK was also demonstrated using an activator
of p38 MAPK, anisomycin. Activation of p38 MAPK prior to ischaemia by
administration of anisomycin immediately preceding ischaemia or as a trigger (i.e.,
administration followed by washout) both elicited protection against infarction and
apoptosis, and was associated with reduced p38 MAPK activation upon reperfusion.
The mechanism of these experimental observations was not investigated, but may
relate to down-stream effectors of p38 MAPK, such as the small heat-shock protein,
HSP27.
4.1 The neonatal cardiomyocytes in culture
The attempt to establish a cell culture model of preconditioning using neonatal
cardiomyocytes had, as basis, the aim to enable one to elucidate the cardiac specific
signal transduction pathways more accurately, as it would exclude the influence of non-
cardiac cells. Furthermore, it potentially offered a way of doing multiple experiments (i.e.
looking at different signal transduction components, and even different end-points)
using a single cell culture preparation, and thus enable rapid progression of the
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investigation. The use of isolated rat hearts limits one to a single experimental situation,
and sets of at least 6 hearts per experimental point have to be performed.
4.1.1 Establishing the MTT method for determination of cell viability
Before it was attempted to set up a model of preconditioning in neonatal
cardiomyocytes, a method of determining cell viability had to be established first. The
MTT assay was chosen, as it has been a well-established method in assessing the
effect of anti-cancer drugs in oncology research, and was also gaining popularity in
cardiac research (Ghosh et al 2001, Gomez et al 1997, Ferrera et al 1993, Punn et al
2000).
Other methods employed to measure viability include osmotic fragility using trypan blue
(Baines et al 1999) and morphological changes (Nojiri et al 1999). All these methods
are labour intensive, and involve microscopic evaluation. Due to the inherent problem of
investigator bias, these evaluations entail blinded evaluation of the samples by more
than one person, which creates another problem - inter observer differences. The MTT
assay is methodologically an easy method, involves one person who can even be the
primary investigator, as the read-out is a spectrophotometer reading that cannot be
manipulated.
The method relies on the conversion of the tetrazolium salt into spectrophotometrically
measurable blue formazan pigments by viable cells. As the reaction involves availability
of NADPH and NADH, they can only take place in cells with intact and functioning
mitochondria. The optimal loading conditions thus had to be determined. The results
show that at the cell density utilized (1,6 X 106 cells/35 mm Petri dish), a concentration
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of 0.25% MTT had to be used. It can be seen that fully viable neonatal cardiomyocyte
cell cultures not subjected to ischaemia cause the release of formazan pigments with an
optical density higher than 0.5 (Fig. 3.1).
4.1.2 Setting up a model of preconditioning in neonatal cardiomyocytes
Numerous investigators have reported the use of neonatal myocyte cell cultures and
simulated ischaemia to study preconditioning (see Table 4.1). In our hands, neonatal
cardiomyocytes could however not be consistently preconditioned by the protocols that
were employed, and using the MTT assay as an endpoint for viability.
Numerous attempts were made to modify the protocols in order to set up a successful
model. In setting up the protocols, different aspects had to be kept in mind:
1. The nature of simulated ischaemia utilized - both for triggering preconditioning, and
as "test ischaemia", i.e. the sustained episode of oxygen deprivation.
2. The duration of both the triggering and the sustained ischaemie period.
3. The duration of reoxygenation following both triggering and sustained "ischaemia".
It can be seen that the number of permutations possible could become extensive and
time consuming.
In the first protocol, a combination of KeN + DOG of 5 min duration was used during the
sustained ischaemia (SI) period. The 00 of both groups did not differ, and were both in
the range of 0.5 - i.e. in the range observed for cells not exposed to ischaemia. This
suggested that the "test" simulated ischaemia was not severe enough to cause cell
damage.
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Table 4.1 Literature review of experimental protocols for preconditioning cultured cardiomyocytes
Author Species Trigger + reoxygenation Sustained ischaemia (SI) Endpoint
or hypoxia
Gray et al (1997) Neonatal rat cardiomyocytes 4 x 90 min hypoxia 9h hypoxia Eukollght 1M viability/
+ 1h reoxygenation cytotoxicity assay
McPherson et al (2001) Chick ventricular myocytes 10 min SI (ischaemia butter) 1h SI (ischaemia buffer) Propidiurn Iodide
+ 10 min reoxygenation + 3h reoxygenation
+ 10 min washout
Rakhit et al (2000) Neonatal rat cardiomyocytes 90 min SI (ischaemia buffer) 6h SI (ischaemia butter) MTT assay
+ 30 min reoxygenation LDH release
Saurin et al (2000) Neonatal rat cardiomyocytes 90 min SI (ischaemia buffer) 2.5h SI (ischaemia buffer) MTT assay
+ 30 min reoxygenation LDH release
Webster et al (1995) Neonatal rat cardiomyocytes 25 min hypoxia 6h hypoxia Arachidonic acid release
+ 30 min reoxygenation Contractile recovery
Zhao et al (1998) Neonatal rat cardiomyocytes 90 min SI (ischaemia buffer) 8h SI (ischaemia buffer) TBE method
+ 30 min reoxygenation LDH release
--- ........ --~
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Thus, for the second protocol, the period of sustained simulated ischaemia was
increased. It was thought that the combination of DOG and KCN would be too severe,
and it was decided to only use KCN for 45 min. This proved effective to induce cell
damage, as the 00 readings of the non-preconditioned cells fell to below 0.3 (see
Figures 3.3 - 3.5).
The preconditioning trigger was similar to that used in the first protocol - 5 min KCN. In
some experiments this was adequate to elicit protection (Fig 3.3), but no consistent
results could be obtained in 21 consecutive experiments. The scattergram in Fig 3.58
shows that the problem was unlikely to be related to an insufficiently long period of
chemical hypoxia, as the 00 readings of most of the experiments were below 0.25.
It is necessary to compare the methodology of authors who have been successful in
preconditioning neonatal cell cultures with our unsuccessful attempts.
(i) The triggers of preconditioning consisted of hypoxia with or without a so-called
"simulated ischaemia buffer". The ischaemia buffer contained (in mmol/I) sodium
lactate 20; KCI 16 at a pH of 6.2. We employed a single-cycle 5 min
administration of KCN without the addition of sodium lactate, high KCI or the
reduction of the pH to 6.2. We do not think that the omission of lactate, a high
potassium concentration or adjustment in the pH was the reason for our inability
to elicit protection. Previous work in our laboratory have shown that 5 min KCN
was adequate to cause rapid depletion of ATP, which would be accompanied by
the same metabolic changes in potassium and lactate as was artificially induced
by the other authors. It is known that it takes longer before hypoxia causes
metabolic derangements in neonatal cell cultures - therefore the duration of
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hypoxia used is 90 minutes in most cases as can be seen in Table 4.1. Therefore
it is unlikely that our trigger was too short or not severe enough to elicit
preconditioning.
(ii) The time period for hypoxia with simulated ischaemia (SI) ranges from at least 1h
to 8h. As discussed above, 45 min KeN was effective to induce cell damage, and
does not explain the inability to set up the model.
(iii) It should also be noted that reoxygenation after SI is not commonly used. Our
model thus did not differ from established models in this respect.
(iv) The endpoints employed in other studies included the MTT assay, the TBE
method, propidium iodide, and LDH release measurement. The inability to
demonstrate protection was therefore unlikely due to the inappropriate use of the
MTT staining method.
It seems as if variations in the triggering and/or reoxygenation period following the
triggering phase may have been useful in our efforts to elicit preconditioning, but in view
of the time it could potentially consume, it was decided not to pursue that course.
Investigations into other reasons why the neonatal cardiomyocytes could not
successfully and consistently precondition were discussed in the results section, but
produced no definitive answers to the problem. One important aspect must be pointed
out: sufficient attention was given to the effect of the age of the rat pups, and the
confluence of the cultures, i.e. the maturity of the cells. This is important, as the
sensitivity of neonatal cells to ischaemia is age dependent. Ostadalova et al in (1998)
performed experiments with 1, 4, and 7-day old neonatal rat isolated perfused hearts.
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They found that preconditioning with 3 x 3 min global ischaemia, separated by 5 min
reperfusion, and followed by 40/60 min global ischaemia only protected the 7 day old
neonatal hearts and not the 1, and 4 day old neonatal hearts. Awad et al (1998)
performed similar experiments with 4, 7, 14, and 21-day old rat hearts, which were
isolated and perfused in Langendorff mode. They found that preconditioning afforded
cardioprotection to the 14, and 21-day old rats only and not the 4, and 7-day old
neonatal rat hearts. This group concluded that protection by preconditioning develops
after 7 days. The possibility that the 2-4 day old neonatal rat hearts may have been too
young to elicit the protection afforded by preconditioning must therefore be considered.
However, other researchers have been able to precondition neonatal cardiomyocytes.
These results indicate that cell maturity can definitely influence outcomes, however
even taking this into account, we could not identify a remediable factor bearing on this in
our work.
Not only were we unable to consistently elicit ischaemie preconditioning in neonatal
cells, but problems were also experienced with pharmacological preconditioning. It was
known from previous work done in both our laboratory (Marais et al 2001 b) and others
(Miyawaki et al 1997b), that the isolated perfused rat heart could be preconditioned with
beta-adrenergic stimulation. However, isoproterenol (10-7 M) was not able to elicit
protection in neonatal cells, probably due to the fact that the 00 reading was above 0.5
for both cell groups. It is thus possible that the neonatal cardiomyocytes were resistant
to ischaemia, i.e. a maturity related effect, or that the episode of sustained simulated
ischaemia was indeed insufficient in these particular sets of experiments.
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In conclusion: It was not possible to consistently precondition neonatal cardiomyocytes
and it seems likely that further modification of the triggering protocol, particularly the
duration of ischaemia and reperfusion, could have been useful. Another possibility
would be to use older neonates.
4.2 Isolated adult cardiomyocytes
A reliable model of preconditioning was essential before proceeding to investigate the
signal transduction pathways involved in its protection. It was decided to use the adult
cardiomyocyte model, which has been shown in our laboratory to precondition
successfully (H. Strijdom, unpublished observations).
Isolated adult cardiomyocyte models are well established in investigations of myocardial
protection against ischaemia. Preconditioning initiated by either a short period of cell
pelletting or by suspension of cells in glucose-free buffer shares many features with
preconditioning in the intact heart, including the adenosine (Armstrong et al 1994), PKC
(Liu et al 1999), and KATP(Liu et al 1998) dependence of protection. The trypan blue
exclusion method is a well-established method for cell viability (Armstrong et al 1995,
Armstrong et al 1999, Baines et al 1999, Liu et al 1999). However, the use of the MTT
assay to measure viability in isolated cardiomyocytes is not common, and it was
decided to utilize the method developed for the neonatal cardiomyocytes.
The preconditioning protocol employed in the isolated adult rat cardiomyocyte model
successfully protected the cells against hypoxia. This was evident by a significant
increase in viability, expressed as the percentage of trypan blue excluding cells, when
comparing the Non-PC groups to the PC groups. The successful preconditioning was
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further proven by the MTT assay expressed as OD/mg protein/ml. The MTT assay
results were comparable with those obtained by the trypan blue exclusion method
(results not shown) and this confirmed the effectiveness of this assay as a reliable
method to test cell viability.
In conclusion: Isolated adult cardiomyocytes could be protected from hypoxia-induced
damage by preconditioning, and the MTT assay could be used to determine cell
viability.
However, this model, although successful in demonstrating preconditioning, could not
provide us with sufficient material to perform subsequent simultaneous investigations on
p38 MAPK, caspase-3 and PARP cleavage and hence it was decided to use the
isolated perfused heart.
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4.3 The Isolated perfused heart provided a reliable model of preconditioning
4.3.1 Infarct size reduction
Preconditioning with both ischaemia and beta-adrenergic stimulation with isoproterenol
(IPC and ~PC respectively) significantly and convincingly reduced the infarct size after
ischaemia/reperfusion compared to Non-PC hearts (Fig 3.8). TTC staining to quantify
infarct size is considered the gold standard to determine the protective effect of
ischaemie and pharmacological preconditioning and has been used by, amongst others,
Baines et al (1997) in the isolated rabbit heart, Kitakaze et al (2000) in dog hearts, and
Piot et al (1997) in isolated rat hearts.
Although the protective effect of ~PC has been reported before (Asimakis et al 1994,
Marais et al 2001 b), no data has ever been published concerning its effect on infarct
size. These results are thus unique. It may not appear to be an important point at first,
but the issue is more complex. Recent data from our own laboratory (unpublished
observations) suggested that the end-point used in preconditioning experiments is very
important in determining the outcome. There is a distinct difference between infarct size
and functional recovery, and protection as assessed by one end-point does not
automatically imply protection as assessed by another. This seems to imply that
different mechanisms of protection are active. Therefore, the finding that ~PC and IPC
both protect against infarction may indicate that the protection mediated by both triggers
utilize the same mechanisms or signal transduction pathways.
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The difference between the decrease in infarct size of IPC and ~PC were not
statistically different, which suggested that ~PC was as effective as IPC in the reduction
of infarct size. The importance of this observation are to be found in the potential clinical
utilization of the intervention. Ischaemic preconditioning is regarded as the most potent
form of protection yet described against ischaemia and infarction (Kloner et al 1998).
The ultimate aim of all investigations in this field is to define the mechanism, in order to
be able to prepare a pharmacological substance that can be administered to patients to
protect them against foreseen or unforeseen ischaemic events. Ideally, pharmacological
preconditioning should be as effective as possible. With this in mind the confirmation
that ~PC is at least as potent as IPC to protect against infarction assumes particular
significance.
4.3.2 Reduction in apoptosis
The results presented in this study also show that both IPC and ~PC protect against the
apoptosis component of ischaemia/reperfusion injury. In this regard, the first question
that must be addressed is the reliability of the method of apoptosis detection. Apoptosis
was detected by using Western blotting to show caspase-3 activation and PARP
cleavage.
These parameters are widely accepted and are reliable. Other methods that are
commonly used to detect apoptosis include the TUNEL assay and DNA fragmentation
using ELISA or gel electrophoresis. The TUNEL assay detects nick-end labeling of DNA
of both single and double stranded DNA, which is present in both necrosis and
apoptosis (Froelich-Ammon et al 1995). DNA fragmentation is not considered the most
elegant way to detect apoptosis, and is not a quantitative method.
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Measuring caspase-3 activation is the method used in more recent studies in this field
(Table 1.2), and the PARP fragmentation is a more reliable parameter than DNA
fragmentation (Gu et al 1995, Lazebnik et al 1994, Tewari et al 1995). We therefore
regard the findings obtained in this study as valid proof of reduced apoptosis.
Ischaemic preconditioning has been shown to decrease apoptosis by, amongst others,
Liu et al (2001) in isolated chick cultured cardiomyocytes and Piot et al (1997) in the
isolated rat heart. Our results showing that IPC reduces apoptosis are thus in
agreement with their findings. The finding that 0PC reduces both caspase-3 activation
and PARP cleavage and thus apoptosis are novel findings, as was the case with
protection against infarction. At the same time the question can be posed whether this is
such an unexpected finding - i.e. whether the protection against apoptosis is divorced
form the protection against infarction, or whether the reduced apoptosis is only the
consequence of reduced damage induced by sustained ischaemia. It is not possible to
answer this question with the information available from these experiments. One
possible way to obtain an answer would be to determine LDH or CK release into the
effluent during reperfusion. On the other hand, it is known that some cells undergoing
apoptosis may switch to necrosis, and would then release cardiac enzymes, rendering
this parameter useless. Indeed, Gottlieb et al (1999) has noted that for this reason the
distinction between apoptosis and necrosis in the myocardium may be an elusive goal
to pursue, and that it may be wiser to include both concepts in a wider theme, namely
"reperfusion damage". Another way to investigate whether separate anti-apoptotic
mechanisms were activated would be to test whether IPC or 0PC could protect against
other mediators of apoptosis. If this were the case, it would support the concept of the
involvement of separate pathways in the activation of apoptosis and mediators of
necrosis.
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In the absence of definite scientific evidence, our results could indicate that the two
triggers of preconditioning (IPC and ~PC) have a common pathway which protect
against apoptosis and necrosis.
4.3.3 Mechanism of protection: Can the protection against necrosis and
apoptosis be attributed to p38 MAPK?
Our data clearly show that protection against necrosis and apoptosis was accompanied
by decreased activation of p38 MAPK upon reperfusion. The question was therefore
whether reduced p38 MAPK activation was the cause or consequence of protection.
The role of p38 MAPK activation as a mechanism of protection remains controversial.
Weinbrenner et al (1997) and Barancik et al (1999), showed that activation of p38
MAPK during sustained ischaemia was beneficial to the ischaemic heart and have
attributed the protection to the activation of heat shock protein 27 (HSP27). This protein
causes stabilization of the actin and fondrin proteins, which are involved in maintaining
plasma membrane integrity. Others, including Marais et al (2001 a) and Sato et al
(2000), have shown that decreased activation of p38 MAPK during sustained
ischaemia, and inhibition of p38 MAPK activation with the specific p38 MAPK inhibitor,
SB 203580, protected against ischaemia. Also, there is sufficient evidence from the
literature that p38 MAPK is involved in apoptosis under many harmful situations,
including oxidative stress, which is a component of ischaemia/reperfusion (Han et al
2001 ).
In conclusion: IPC and ~PC caused a significant reduction in infarct size and apoptosis
as determined by caspase-3 activation and PARP cleavage at the end of
ischaemia/reperfusion, which was associated with a reduction in p38 MAPK activation
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upon reperfusion. The question that remains to be addressed concerns the role of p38
MAPK in preconditioning.
4.4 Defining the role of p38 MAPK in protection against ischaemia/reperfusion
Apart from the possibility that attenuated activation of p38 MAPK during sustained
ischaemia was involved in the protective effect of preconditioning, another aspect had to
be kept in mind. Ischaemia/reperfusion of 5 minutes duration, such as used in our
preconditioning protocol, has been shown to cause an increase in p38 MAPK activation
(Armstrong et al 1999, Bogoyevitch et al 1996, Marais et al 2001 a, Maulik et al 1996).
The possibility that p38 MAPK was involved in preconditioning thus had to be
approached from two viewpoints - attenuated activation during sustained ischaemia as
a mediator of the protective effect, and activation of p38 MAPK as a trigger of
protection. To investigate these aspects, two approaches were used:
1. inhibition of p38 MAPK with SB 203580 during the triggering and mediating phase,
and
2. activation of p38 MAPK with anisomycin during the triggering and mediating phase.
4.4.1 The inhibition of p38 MAPK activation
4.4.1.1 Attenuation of p38 MAPK activation as mediator of protection
Administration of SB 203580 before sustained ischaemia/reperfusion resulted in
significant protection against ischaemia/reperfusion damage as evidenced by a
reduction in infarct size and markers of apoptosis. The protection was of the same
magnitude as that of IPC. These results suggested that the attenuation of p38 MAPK
activation during ischaemia was not just an associated finding, and provided evidence
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that attenuated p38 MAPK activation could indeed be a mediator of the protective effect
of ischaemic preconditioning (Fig 3.12, 3.13 and 3.14).
These results contradict the findings of Weinbrenner et al (1997) who found that p38
MAPK was activated in preconditioned isolated rabbit cardiac cells during sustained
ischaemia, and that SB 203580 added prior to simulated ischaemia abolished the
reduction in fragility. Their results therefore suggested that p38 MAPK activation acted
as a mediator of protection. Nakano et al (2000b) found no role for p38 MAPK in
reducing infarct size in vivo in rabbits when SB 203580 was administered before
sustained ischaemia. However, our results are in agreement with data by Ping et al
(1999), who have shown that p38 MAPK activation was downregulated by six cycles of
ischaemia/reperfusion and Sato et al (2000), who found that SB 203580 administered
before sustained ischaemia decreased infarct size in isolated rat hearts. Similarly,
Marais et al (2001 a) found that, in isolated rat cardiomyocytes, SB 203580 when
administered before hypoxia caused a significant improvement in both cell morphology
and viability. Saurin et al (1999) also provided compelling evidence that the protective
effect of preconditioning was accompanied by attenuated activation of p38 MAPK-a
during sustained ischaemia.
Although the model used by Han et al (2001) was a fibroblast cell line and not cardiac
cells, the results of this excellent study clearly showed that a decrease in p38 MAPK
activation was associated with a decrease in apoptosis. This is in agreement with the
current notion that activation of the p38 MAPK is pro-apoptotic in many situations (Chen
et al 1996, Johnson et al 1996, Obata et al 2000) and although not conclusive, is
certainly supportive of our findings.
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The exact reason for the above disparate results are not clear. It should be noted that
species differences may be important - rabbits and rats are not necessarily
comparable. Whereas the literature supports a role for adenosine as a trigger of
preconditioning in the rabbit, there is no consensus on its role as a trigger in the rat
(Ganote 2000). The role of activation of PKC in the rat has also not been as equivocal
as was the case in the rabbit (Simkhovich et al 1998). As noted before, the end-point
used was also important - measuring osmotic fragility may not be relevant in
comparison to evaluating protection against necrosis or apoptosis.
4.4.1.2 p38 MAPK as a trigger of protection
As mentioned before, an IPC protocol of 5 min ischaemia causes activation of p38
MAPK (Sato et al 2000, Marais et al 2001 a). The role of p38 MAPK activation could
therefore be assessed by inhibiting it during the triggering phase. The inhibition of p38
MAPK activation by bracketing the ischaemie preconditioning protocol did not abolish
the protective effect of IPC on infarct size (Fig 3.12), but caused a slight but significant
increase in markers of apoptosis (Fig 3.14 and Fig 3.15).
Our results are in disagreement with data by Sato et al (2000) who found that SB
203580, when given before the preconditioning protocol, abolished the infarct-reducing
effect of IPC. Also, in the study on the fibroblast cell line by Han et al (2001) referred to
above, inhibition of p38 MAPK during the triggering phase abolished the protection
against radical oxygen species.
Stellenbosch University http://scholar.sun.ac.za
102
Our results agree with those of Marais et al (2001 a), who found that in isolated rat
cardiomyocytes, administration of SB 203580 before and during the IPC protocol had no
effect on morphology and viability after 2 hours of hypoxia compared to untreated
preconditioned isolated rat cardiomyocytes.
In conclusion: The inhibition of p38 MAPK activation with SB 203580 during the IPC
protocol did not abolish the protective effect of IPC on infarct size reduction, but caused
a slight increase in apoptosis. This suggests that separate pathways are operating in
mediating protection against necrosis and apoptosis.
4.4.2 The activation of p38 MAPK
In order to confirm the validity of the conclusions made in the previous section by using
inhibitors of p38 MAPK, the opposite approach was used, namely to observe the effect
of activators of p38 MAPK. In order to elucidate the role of p38 MAPK activation as
either a mediator or as a trigger of the protective effect of preconditioning, anisomycin,
an activator of p38 MAPK, was administered (i) immediately preceding sustained
ischaemia and (ii) for 10 min followed by a washout period before sustained ischaemia.
4.4.2.1 Activation of p38 MAPK with anisomycin either as a mediator or as a
trigger elicits protection
p38 MAPK activation with (i) anisomycin immediately before sustained ischaemia (i.e.
as mediator) or (ii) for 10 min followed by washout (i.e. as trigger) resulted in a
significant decrease in infarct size, (Fig 3.16), and less apoptosis as evidenced by
reduced caspase-3 activation. The effect on PARP cleavage was not as pronounced as
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that of caspase-3 activation due to large standard errors. A representative blot is shown
in Fig 3.19, which demonstrates the extent of PARP cleavage under these
circumstances. p38 MAPK activity was significantly lower upon reperfusion in both
groups treated with anisomycin.
The question that needs to be addressed is how the data with p38 MAPK activation fits
in with the data obtained in experiments using the inhibitor, SB 203580. The observation
was made that anisomycin administered before sustained ischaemia elicited protection
against both necrosis and apoptosis, both when administered as trigger and as
mediator, whereas the inhibition of p38 MAPK mediated protection during sustained
ischaemia, and only seemed to play a role as a trigger in the protection against
apoptosis.
If attenuation of p38 MAPK activation was indeed a mediator of protection, one would
expect anisomycin mediated activation of p38 MAPK during sustained ischaemia to
decrease protection against infarction and apoptosis. One explanation is that the
administration of anisomycin immediately prior to sustained ischaemia did not result in
sustained p38 MAPK activation during ischaemia - the finding that p38 MAPK activity
was decreased at the end of reperfusion supports this notion. It is therefore possible
that the unexpected beneficial effect of anisomycin can be attributed to the activation of
protective mechanisms prior to sustained ischaemia. The only approach to activate p38
MAPK during ischaemia alone would be to infuse the agent directly into the myocardium
- this was done by Barancik et al (2000) in similar work in a regional infarct model in
pigs.
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The role of p38 MAPK as a trigger is also questioned by these results - if it was true
that p38 MAPK was indeed not important as a trigger of protection against necrosis,
anisomycin would have been expected to have no effect on it. On the other hand, as
inhibition of p38 MAPK during the triggering phase caused an increase in apoptosis, it
would be expected that anisomycin mediated activation of p38 MAPK should decrease
apoptosis, which did occur.
One approach would be to regard the two sets of anisomycin experiments as variants of
the same phenomenon - namely that the activation of p38 MAPK prior to sustained
ischaemia activates protective downstream mechanisms which protect against both
necrosis and apoptosis. This would take into account the fact that p38 MAPK was not
activated during sustained ischaemia in this model. Indeed, this data is in agreement
with Weinbrenner et al (1997) who found that, in isolated rabbit cardiomyocytes,
anisomycin added prior to simulated ischaemia was as protective as IPC. Similarly
Barancik et al (1999) showed that, in the pig heart, anisomycin reduced infarct size
when administered before IIR. Also, in the isolated rat heart, Sato et al (2000)
documented that the activation of p38 MAPK with anisomycin mimicked the infarct size-
lowering effects of IPC.
What could this downstream effector be? The strongest candidate is HSP27, a small
heat shock protein that is activated by p38 MAPK activation. HSP27 has been
documented to have strong anti-apoptotic effects, as well as an actin stabilizing action
that could contribute to protection against ischaemia induced cell disruption (Guay et al
1997). It can be postulated that the activation of HSP27 by anisomycin (acting via
activation of p38 MAPK) elicited the protection that was observed.
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This explanation does not account for the fact that SB 203580 did not abolish the
protective effect of a 3 X 5 min cycle of ischaemic preconditioning. On the other hand, it
may indicate that p38 MAPK activation only contributed to part of the protective effect of
such a multi-cycle ischaemie preconditioning protocol, and that other factors
independent of p38 MAPK were also involved. This would explain why a small increase
in apoptosis was observed when SB 203580 bracketed the ischaemic preconditioning
protocol, yet no increase in infarct size was observed. It has been shown that the
activation of p38 MAPK which is seen with repetitive intermittent ischaemia as used in a
multi-cycle preconditioning protocol decreases with every cycle (Marais et al 2001 a),
which may mean that only the initial activation of p38 MAPK is of any importance.
Furthermore, there is evidence that multi-cycle ischaemie preconditioning protocols
activate more than one signal transduction pathway. Sandhu et al (1997) have found
that inhibitors of adenyl cyclase could attenuate the protective effect of a single episode
of ischaemie preconditioning, but not of a multi-cycle protocol. Unpublished data from
our own laboratory also suggest a more marked role for p38 MAPK as trigger in a single
episode ischaemie preconditioning protocol.
Other factors have to be considered too. Anisomycin also activates the JNK stress
kinases. In order to evaluate the contribution of JNK to the observed results, the
experiments would have to be repeated using an inhibitor of JNK, such as curcumin or
SP 600125. However, JNK activation is unlikely to be involved in the activation of
protective mechanisms as it is usually involved in activating apoptosis. Although
anisomycin activates p38 MAPK, it is not known which isoform of p38 MAPK is
activated. It is possible that administration of 5 IlM anisomycin activated p38~ in the
isolated adult rat perfused heart, an isoform known to be anti-apoptotic and thus
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protective. Unfortunately, no antibodies are yet available to distinguish between the
isoforms.
In conclusion: p38 MAPK activation with anisomycin administered either as a trigger or
as a mediator decreased infarct size and apoptosis, which suggests a role for p38
MAPK activated downstream effectors as protectors against ischaemia/reperfusion
damage. The logistical problem of being unable to activate p38 MAPK during ischaemia
only (and not prior to it) makes it impossible to make valid deductions about the role of
p38 MAPK activation during ischaemia. The data using the p38 MAPK inhibitor, SB
203580, therefore must carry more weight in the assessment of the role of p38 MAPK.
Furthermore, activation of p38 MAPK as a trigger caused a reduction in infarct size and
suggests a role for p38 MAPK as a trigger of preconditioning. Due to the possibility that
a multi-cycle protocol of ischaemic preconditioning may activate multiple mechanisms,
the data using anisomycin should be considered to be more important to define the role
of p38 MAPK activation than the data in which the inhibitor of p38 MAPK was used.
These concepts are summarized in Fig 4.1 and Fig 4.2
Final conclusion:
These results provide evidence for the involvement of the p38 MAPK pathway in the
protective effect of preconditioning against ischaemia/reperfusion damage. Manipulation
of this pathway may constitute a new therapeutic approach to counter the detrimental
consequences of ischaemia/reperfusion.
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Fig 4.1 Role of p38 MAPK activation
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